<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article article-type="review-article" dtd-version="2.3" xml:lang="EN" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">Front. Bioeng. Biotechnol.</journal-id>
<journal-title>Frontiers in Bioengineering and Biotechnology</journal-title>
<abbrev-journal-title abbrev-type="pubmed">Front. Bioeng. Biotechnol.</abbrev-journal-title>
<issn pub-type="epub">2296-4185</issn>
<publisher>
<publisher-name>Frontiers Media S.A.</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="publisher-id">1469393</article-id>
<article-id pub-id-type="doi">10.3389/fbioe.2024.1469393</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Bioengineering and Biotechnology</subject>
<subj-group>
<subject>Review</subject>
</subj-group>
</subj-group>
</article-categories>
<title-group>
<article-title>Reactive oxygen species (ROS)-responsive biomaterials for treating myocardial ischemia-reperfusion injury</article-title>
<alt-title alt-title-type="left-running-head">Zhang et al.</alt-title>
<alt-title alt-title-type="right-running-head">
<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.3389/fbioe.2024.1469393">10.3389/fbioe.2024.1469393</ext-link>
</alt-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" equal-contrib="yes">
<name>
<surname>Zhang</surname>
<given-names>Ying</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
<xref ref-type="author-notes" rid="fn001">
<sup>&#x2020;</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/2801717/overview"/>
<role content-type="https://credit.niso.org/contributor-roles/visualization/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/>
<role content-type="https://credit.niso.org/contributor-roles/Writing - review &#x26; editing/"/>
<role content-type="https://credit.niso.org/contributor-roles/investigation/"/>
</contrib>
<contrib contrib-type="author" equal-contrib="yes">
<name>
<surname>Jiang</surname>
<given-names>Mantang</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="author-notes" rid="fn001">
<sup>&#x2020;</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/2827796/overview"/>
<role content-type="https://credit.niso.org/contributor-roles/investigation/"/>
<role content-type="https://credit.niso.org/contributor-roles/visualization/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Wang</surname>
<given-names>Tao</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
<xref ref-type="corresp" rid="c001">&#x2a;</xref>
<uri xlink:href="https://loop.frontiersin.org/people/2727457/overview"/>
<role content-type="https://credit.niso.org/contributor-roles/conceptualization/"/>
<role content-type="https://credit.niso.org/contributor-roles/funding-acquisition/"/>
<role content-type="https://credit.niso.org/contributor-roles/investigation/"/>
<role content-type="https://credit.niso.org/contributor-roles/supervision/"/>
<role content-type="https://credit.niso.org/contributor-roles/visualization/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/>
<role content-type="https://credit.niso.org/contributor-roles/Writing - review &#x26; editing/"/>
</contrib>
</contrib-group>
<aff id="aff1">
<sup>1</sup>
<institution>Natural and Biomimetic Medicine Research Center</institution>, <institution>Tissue-Orientated Property of Chinese Medicine Key Laboratory of Sichuan Province</institution>, <institution>West China Hospital</institution>, <institution>Sichuan University</institution>, <addr-line>Chengdu</addr-line>, <country>China</country>
</aff>
<aff id="aff2">
<sup>2</sup>
<institution>Institute of Integrated Traditional Chinese and Western Medicine</institution>, <institution>West China Hospital</institution>, <institution>Sichuan University</institution>, <addr-line>Chengdu</addr-line>, <country>China</country>
</aff>
<author-notes>
<fn fn-type="edited-by">
<p>
<bold>Edited by:</bold> <ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/1726450/overview">Donglin Xia</ext-link>, Nantong University, China</p>
</fn>
<fn fn-type="edited-by">
<p>
<bold>Reviewed by:</bold> <ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/2803251/overview">Yuda Zhu</ext-link>, The Affiliated Hospital of Southwest Medical University, China</p>
<p>
<ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/2803540/overview">Jinyang Li</ext-link>, Southwest Jiaotong University, China</p>
</fn>
<corresp id="c001">&#x2a;Correspondence: Tao Wang, <email>terrywang1126@scu.edu.cn</email>
</corresp>
<fn fn-type="equal" id="fn001">
<label>
<sup>&#x2020;</sup>
</label>
<p>These authors have contributed equally to this work</p>
</fn>
</author-notes>
<pub-date pub-type="epub">
<day>02</day>
<month>09</month>
<year>2024</year>
</pub-date>
<pub-date pub-type="collection">
<year>2024</year>
</pub-date>
<volume>12</volume>
<elocation-id>1469393</elocation-id>
<history>
<date date-type="received">
<day>23</day>
<month>07</month>
<year>2024</year>
</date>
<date date-type="accepted">
<day>21</day>
<month>08</month>
<year>2024</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright &#xa9; 2024 Zhang, Jiang and Wang.</copyright-statement>
<copyright-year>2024</copyright-year>
<copyright-holder>Zhang, Jiang and Wang</copyright-holder>
<license xlink:href="http://creativecommons.org/licenses/by/4.0/">
<p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</p>
</license>
</permissions>
<abstract>
<p>Myocardial ischemia-reperfusion injury (MIRI) is a critical issue that arises when restoring blood flow after an ischemic event in the heart. Excessive reactive oxygen species (ROS) production during this process exacerbates cellular damage and impairs cardiac function. Recent therapeutic strategies have focused on leveraging the ROS microenvironment to design targeted drug delivery systems. ROS-responsive biomaterials have emerged as promising candidates, offering enhanced therapeutic efficacy with reduced systemic adverse effects. This review examines the mechanisms of ROS overproduction during myocardial ischemia-reperfusion and summarizes significant advancements in ROS-responsive biomaterials for MIRI treatment. We discuss various chemical strategies to impart ROS sensitivity to these materials, emphasizing ROS-induced solubility switches and degradation mechanisms. Additionally, we highlight various ROS-responsive therapeutic platforms, such as nanoparticles and hydrogels, and their unique advantages in drug delivery for MIRI. Preclinical studies demonstrating the efficacy of these materials in mitigating MIRI in animal models are reviewed, alongside their mechanisms of action and potential clinical implications. We also address the challenges and future prospects of translating these state of the art biomaterial-based therapeutics into clinical practice to improve MIRI management and cardiac outcomes. This review will provide valuable insights for researchers and clinicians working on novel therapeutic strategies for MIRI intervention.</p>
</abstract>
<kwd-group>
<kwd>myocardial ischemia-reperfusion injury</kwd>
<kwd>ROS-responsive biomaterials</kwd>
<kwd>nanoparticals</kwd>
<kwd>hydrogels</kwd>
<kwd>biomimetic biomaterials</kwd>
</kwd-group>
<contract-num rid="cn001">82000266</contract-num>
<contract-sponsor id="cn001">National Natural Science Foundation of China<named-content content-type="fundref-id">10.13039/501100001809</named-content>
</contract-sponsor>
<custom-meta-wrap>
<custom-meta>
<meta-name>section-at-acceptance</meta-name>
<meta-value>Biomaterials</meta-value>
</custom-meta>
</custom-meta-wrap>
</article-meta>
</front>
<body>
<sec id="s1">
<title>1 Introduction</title>
<p>Myocardial infarction (MI) remains the leading cause of morbidity and mortality worldwide, underscoring the urgent need for innovative therapeutic strategies (<xref ref-type="bibr" rid="B82">Reed et al., 2017</xref>; <xref ref-type="bibr" rid="B54">Laforgia et al., 2022</xref>). MI is characterized by the occlusion of coronary arteries, resulting in a deprivation of oxygen and nutrients to the damaged myocardium. Re-establishing blood flow through reperfusion, typically via percutaneous coronary intervention or thrombolysis, is critical for saving the ischemic myocardium (<xref ref-type="bibr" rid="B100">Thygesen et al., 2007</xref>; <xref ref-type="bibr" rid="B86">Saito et al., 2023</xref>). However, this process induces a series of harmful effects, including oxidative stress caused by a surge in reactive oxygen species (ROS), calcium overload, and a strong inflammatory response, leading to further myocardial damage, known as myocardial ischemia-reperfusion injury (MIRI) (<xref ref-type="bibr" rid="B120">Yellon and Hausenloy, 2007</xref>; <xref ref-type="bibr" rid="B2">Algoet et al., 2023</xref>; <xref ref-type="bibr" rid="B70">Liu Y. et al., 2023</xref>).</p>
<p>ROS, including superoxide anion (O<sub>2</sub>
<sup>&#x2022;&#x2212;</sup>), hydroxyl radical (<sup>&#x2022;</sup>OH), and hydrogen peroxide (H<sub>2</sub>O<sub>2</sub>), are natural byproducts of cellular metabolism, primarily generated in mitochondria during oxidative phosphorylation (<xref ref-type="bibr" rid="B91">Sies et al., 2022</xref>). Under normal physiological conditions, ROS are tightly regulated by endogenous antioxidant systems, maintaining redox homeostasis. However, during myocardial I/R, the abrupt reintroduction of oxygen during reperfusion disrupt the balance between ROS production and scavenging, resulting in an uncontrolled burst of ROS from various sources, including the mitochondria, xanthine oxidase, NADPH oxidases, and uncoupled nitric oxide synthase (NOS). This excessive ROS generation triggers a cascade of deleterious events, including lipid peroxidation, protein oxidation, DNA damage, inflammation, and various forms of programmed cell death (e.g., apoptosis, pyroptosis, ferroptosis), ultimately exacerbating myocardial injury and dysfunction (<xref ref-type="bibr" rid="B14">Cadenas, 2018</xref>; <xref ref-type="bibr" rid="B27">Dubois-Deruy et al., 2020</xref>).</p>
<p>Over the past few decades, significant progress has been made in developing anti-MIRI drugs (<xref ref-type="bibr" rid="B44">Ibanez et al., 2015</xref>; <xref ref-type="bibr" rid="B134">Zhou et al., 2021</xref>), however, systemic drug administration faces challenges such as poor targeting, limited efficacy, and potential toxic side effects. Recent advancements in nanotechnology and biomaterials have paved the way for creating targeted therapeutic strategies that deliver drugs specifically to ischemia-reperfusion injured myocardium (<xref ref-type="bibr" rid="B73">Luo et al., 2023</xref>). The unique ischemia-reperfusion microenvironment (IME), characterized by acidosis, elevated ROS levels, and massive inflammatory cell infiltration, has become a critical target for developing controlled-release strategies for anti-MIRI drugs (<xref ref-type="bibr" rid="B39">Hausenloy and Yellon, 2013</xref>; <xref ref-type="bibr" rid="B61">Li and Gao, 2023</xref>).</p>
<p>Among the various strategies targeting the IME, ROS-responsive nanomaterials are currently the most advanced and promising. These materials are engineered to specifically detect abnormal ROS levels at the site of injury and to trigger the controlled release of therapeutic agents or modulation of cellular signaling pathways, thereby improving tissue inflammation (<xref ref-type="bibr" rid="B24">Chung et al., 2015</xref>; <xref ref-type="bibr" rid="B58">Lee et al., 2018</xref>; <xref ref-type="bibr" rid="B108">Xia et al., 2023</xref>), impaired angiogenesis (<xref ref-type="bibr" rid="B21">Chen et al., 2021</xref>; <xref ref-type="bibr" rid="B132">Zheng et al., 2022a</xref>), or fibrosis (<xref ref-type="bibr" rid="B96">Surendran et al., 2020</xref>; <xref ref-type="bibr" rid="B29">Gaytan et al., 2023</xref>; <xref ref-type="bibr" rid="B128">Zhang J. et al., 2024</xref>). Strategies for fabricating ROS-responsive biomaterials encompass a diverse array of approaches, primarily based on ROS-induced solubility switches and degradation mechanisms (<xref ref-type="bibr" rid="B60">Lee S. H. et al., 2013</xref>; <xref ref-type="bibr" rid="B112">Xu et al., 2016b</xref>). Solubility switching strategies exploit the reversible transformation of the amphiphilic nature of materials towards ROS, thereby achieving controlled release of the encapsulated therapeutic agent. In contrast, the ROS-induced degradation strategy involves incorporating ROS-labile linkages within the polymer backbone, designed to cleave upon exposure to ROS, leading to material degradation and subsequent release of the therapeutic agent. Biomaterials that utilize ROS-induced solubility switching or degradation elements, including polymeric nanoparticles, injectable hydrogels, and biomimetic nanoparticles, loaded with anti-MIRI drugs possessing antioxidant, anti-inflammatory, pro-survival, or pro-angiogenic properties, have become promising targeted therapeutic strategies for MIRI in the past decade (<xref ref-type="bibr" rid="B7">Bae et al., 2016</xref>; <xref ref-type="bibr" rid="B135">Ziegler et al., 2019</xref>; <xref ref-type="bibr" rid="B63">Li et al., 2020</xref>; <xref ref-type="bibr" rid="B65">Li et al., 2021</xref>; <xref ref-type="bibr" rid="B37">Hao T. et al., 2022</xref>; <xref ref-type="bibr" rid="B42">Hou et al., 2022</xref>; <xref ref-type="bibr" rid="B43">Huang et al., 2022</xref>; <xref ref-type="bibr" rid="B56">Lan et al., 2022</xref>; <xref ref-type="bibr" rid="B62">Li et al., 2022</xref>; <xref ref-type="bibr" rid="B106">Weng et al., 2022</xref>; <xref ref-type="bibr" rid="B130">Zhang X. et al., 2022</xref>). These ROS-responsive nanomedicines have demonstrated their precise targeting and controlled drug release capabilities and achieved enhanced therapeutic effects in MIRI animal models, providing strong support for their future clinical applications.</p>
<p>In this review, we aim to provide a comprehensive overview of the progress in ROS-responsive biomaterials for treating MIRI over the past decade (<xref ref-type="fig" rid="F1">Figure 1</xref>). We summarize the mechanisms underlying ROS overproduction during myocardial I/R, strategies for fabricating ROS-responsive biomaterials, and the current ROS-responsive therapeutic platforms for MIRI intervention. We also discuss the challenges and future prospects of translating these technologies into clinical practice, aiming to improve cardiovascular health and patient outcomes.</p>
<fig id="F1" position="float">
<label>FIGURE 1</label>
<caption>
<p>Schematic representation of ROS-responsive nanomedicines targeting MIRI. bFGF: basic fibroblast growth factor; COF: covalent organic framework; CLP: an amphiphilic copolymer was designed and synthesized by sequentially conjugating luminol and PEG with Ce6; CS-B-NO: chitosan modified by boronate-protected diazeniumdiolate; LP: liposome; NO: nitric oxide; PPTP: PGE<sub>2</sub>-PEG modified tellurium-crosslinked polyethyleneimine; PEG: poly (ethylene glycol); PPS: poly (propylene sulfide); PMVs: platelet mem brane vesicles; PVA: poly (vinyl alcohol); PTPSCs: PLGA-TK-PEG-SS31; TBD: to be determined; TPE: Tetraphenylethene; TSPBA: N1-(4-boronobenzyl)-N3-(4-boronophenyl)-N1,N1,N3,N3-tetramethylpropane-1,3-diaminium.</p>
</caption>
<graphic xlink:href="fbioe-12-1469393-g001.tif"/>
</fig>
</sec>
<sec id="s2">
<title>2 ROS overproduction during myocardial I/R</title>
<p>The excessive generation of ROS is a pivotal factor in MIRI. This ROS storm triggers a cascade of deleterious events, including mitochondrial dysfunction and lipid peroxidation, leading to cardiomyocyte necrosis and various forms of programmed cell death such as apoptosis, pyroptosis, and ferroptosis (<xref ref-type="bibr" rid="B14">Cadenas, 2018</xref>; <xref ref-type="bibr" rid="B30">Gong et al., 2024</xref>). Several recent reviews have well elucidated the mechanisms of ROS generation following myocardial I/R and its complex role in MIRI (<xref ref-type="bibr" rid="B14">Cadenas, 2018</xref>; <xref ref-type="bibr" rid="B13">Bugger and Pfeil, 2020</xref>). Here, we focus on providing a summary of current knowledge about the source and mechanism of ROS overproduction after myocardial I/R from the perspective of different cell types in damaged myocardium, including cardiomyocytes and non-cardiomyocytes (e.g., inflammatory cells, endothelial cells, and platelets). (<xref ref-type="fig" rid="F2">Figure 2</xref>).</p>
<fig id="F2" position="float">
<label>FIGURE 2</label>
<caption>
<p>Schematic illustration of potential ROS sources in injured myocardium during MIRI. O<sub>2</sub>
<sup>&#x2022;&#x2212;</sup> are primarily produced in the mitochondrial ETC. Fe<sup>2&#x2b;</sup> released by the ruptured mitochondria generates &#x2022;OH via Fenton reaction. Mitochondrial NOX also generates O<sub>2</sub>
<sup>&#x2022;&#x2212;</sup>. Damaged antioxidant systems, such as SOD2, fail to adequately remove O<sub>2</sub>
<sup>&#x2022;&#x2212;</sup> or H<sub>2</sub>O<sub>2</sub> leading to the accumulation of ROS. In the extramitochondrial space, NOX and XO play major roles in ROS production during I/R. Excessive ROS causes oxidative damage to lipids, proteins, and nucleic acids, leading to cell death and exacerbating I/R injury. The increased oxidative stress in the extracellular microenvironment of the injured myocardium is mainly attributed to the contents released after the rupture of the plasma membrane of damaged cardiomyocytes, as well as the ROS released by neutrophils, macrophages, endothelial cells, and activated platelets.</p>
</caption>
<graphic xlink:href="fbioe-12-1469393-g002.tif"/>
</fig>
<sec id="s2-1">
<title>2.1 ROS generation in cardiomyocytes</title>
<sec id="s2-1-1">
<title>2.1.1 Mitochondrial electron transport chain (ETC)</title>
<p>Mitochondria are the primary sources of ROS production in damaged cardiomyocytes during myocardial I/R (<xref ref-type="bibr" rid="B13">Bugger and Pfeil, 2020</xref>). The ETC complexes, particularly complexes I and III, are key sites where electron leakage occurs, leading to the formation of superoxide anion (O<sub>2</sub>
<sup>&#x2022;&#x2212;</sup>). During ischemia, the activity of complex I is inhibited due to oxygen depletion, causing electron accumulation. Upon reperfusion, these electrons react with the reintroduced oxygen, generating a significant amount of O<sub>2</sub>
<sup>&#x2022;&#x2212;</sup> through reverse electron transport (RET) (<xref ref-type="bibr" rid="B78">Paradies et al., 2004</xref>; <xref ref-type="bibr" rid="B20">Chen et al., 2008</xref>; <xref ref-type="bibr" rid="B102">Vinogradov and Grivennikova, 2016</xref>). This process is exacerbated by the accumulation of succinate during ischemia, which is rapidly oxidized upon reperfusion, driving RET and enhancing ROS production (<xref ref-type="bibr" rid="B22">Chouchani et al., 2014</xref>). Complex II also contributes to ROS generation, though to a lesser extent than complexes I and III (<xref ref-type="bibr" rid="B22">Chouchani et al., 2014</xref>; <xref ref-type="bibr" rid="B23">Chouchani et al., 2016</xref>). Additionally, Fe<sup>2&#x2b;</sup> released by the ruptured mitochondria reacts with intracellular H<sub>2</sub>O<sub>2</sub>, triggering the Fenton reaction and generating the highly strong oxidant &#x2022;OH (<xref ref-type="bibr" rid="B31">Gordan et al., 2018</xref>).</p>
</sec>
<sec id="s2-1-2">
<title>2.1.2 NADPH oxidase (NOX)</title>
<p>NADPH oxidases are another critical source of ROS in both cardiomyocytes and non-cardiomyocytes (<xref ref-type="bibr" rid="B48">Kahles and Brandes, 2013</xref>). NOX enzymes, particularly NOX2 and NOX4, are upregulated in response to I/R injury (<xref ref-type="bibr" rid="B12">Braunersreuther et al., 2013</xref>). These enzymes transfer electrons from NADPH to oxygen, producing O<sub>2</sub>
<sup>&#x2022;&#x2212;</sup>. NOX-derived ROS are implicated in various pathophysiological processes, including endothelial dysfunction and inflammation (<xref ref-type="bibr" rid="B79">Paravicini and Touyz, 2008</xref>). Inhibition of NOX activity has been shown to reduce myocardial infarct size and ROS levels (<xref ref-type="bibr" rid="B99">Thirunavukkarasu et al., 2012</xref>; <xref ref-type="bibr" rid="B12">Braunersreuther et al., 2013</xref>), underscoring its significance in I/R injury.</p>
</sec>
<sec id="s2-1-3">
<title>2.1.3 Xanthine oxidase (XO)</title>
<p>Xanthine oxidase is a key enzyme in purine metabolism that generates ROS as a byproduct in cardiomyocytes (<xref ref-type="bibr" rid="B11">Boueiz et al., 2008</xref>). During ischemia, xanthine dehydrogenase is converted to XO, which then produces O<sub>2</sub>
<sup>&#x2022;&#x2212;</sup> and H<sub>2</sub>O<sub>2</sub> during reperfusion. XO-derived ROS contribute significantly to oxidative stress and tissue damage in MIRI (<xref ref-type="bibr" rid="B75">Madesh and Hajnoczky, 2001</xref>; <xref ref-type="bibr" rid="B41">Hool, 2009</xref>). The use of XO inhibitors, such as allopurinol, has demonstrated cardioprotective effects by reducing ROS production and subsequent cellular injury (<xref ref-type="bibr" rid="B32">Grimaldi-Bensouda et al., 2015</xref>).</p>
</sec>
</sec>
<sec id="s2-2">
<title>2.2 ROS generation in endothelial cells (ECs)</title>
<p>ECs are pivotal in the pathophysiology of MIRI and other cardiovascular diseases, largely due to their role as major sources of ROS (<xref ref-type="bibr" rid="B117">Yang et al., 2016</xref>; <xref ref-type="bibr" rid="B19">Chen et al., 2019</xref>; <xref ref-type="bibr" rid="B40">Haybar et al., 2019</xref>). Among the key mechanisms regulated by ECs is the synthesis of nitric oxide (NO), a vasodilator with protective cardiovascular effects, mediated by endothelial nitric oxide synthase (eNOS) (<xref ref-type="bibr" rid="B77">Mount et al., 2007</xref>). Under physiological conditions, eNOS efficiently produces NO, which not only promotes vascular relaxation but also exerts antioxidant effects. However, during oxidative stress, the cofactor tetrahydrobiopterin (BH4), essential for eNOS function, undergoes oxidation, leading to the uncoupling of eNOS. This uncoupling diverts eNOS activity from NO production to the generation of O<sub>2</sub>
<sup>&#x2022;&#x2212;</sup>, thereby increasing ROS levels and exacerbating endothelial dysfunction (<xref ref-type="bibr" rid="B28">Dumitrescu et al., 2007</xref>; <xref ref-type="bibr" rid="B3">Alkaitis and Crabtree, 2012</xref>). Strategies to recouple eNOS, such as supplementation with BH4 or its precursors, have shown promise in reducing ROS production and ameliorating cardiac damage (<xref ref-type="bibr" rid="B5">Antoniades et al., 2006</xref>). Despite the antioxidant role of NO under normal conditions, its interaction with O<sub>2</sub>
<sup>&#x2022;&#x2212;</sup> can result in the formation of peroxynitrite (ONOO<sup>&#x2212;</sup>), a harmful oxidant (<xref ref-type="bibr" rid="B81">Radi, 2013</xref>). The presence of ONOO<sup>&#x2212;</sup> further intensifies oxidative stress, contributing to greater myocardial damage during IR injury (<xref ref-type="bibr" rid="B71">Liu et al., 2005</xref>; <xref ref-type="bibr" rid="B124">Yu et al., 2018</xref>).</p>
</sec>
<sec id="s2-3">
<title>2.3 ROS generation in inflammatory cells</title>
<p>Inflammatory cells, such as neutrophils and macrophages, are recruited to the site of injury during reperfusion. These cells produce large amounts of ROS via their NADPH oxidase systems in response to inflammatory stimuli (<xref ref-type="bibr" rid="B17">Chakraborti et al., 2000</xref>). Neutrophil-derived ROS contribute to tissue damage by exacerbating oxidative stress and promoting further recruitment of inflammatory cells (<xref ref-type="bibr" rid="B46">Jordan et al., 1999</xref>). The interaction between inflammatory cells and damaged endothelium also creates a vicious cycle of ROS production and cellular injury (<xref ref-type="bibr" rid="B52">Knock, 2019</xref>).</p>
</sec>
<sec id="s2-4">
<title>2.4 ROS generation in activated platelets</title>
<p>Platelets also contribute to ROS production after myocardial I/R. During I/R, platelets become activated and release ROS through their mitochondrial pathways and NADPH oxidase systems (<xref ref-type="bibr" rid="B8">Begonja et al., 2005</xref>). Platelet-derived ROS also plays a significant role in amplifying the inflammatory response and promoting thrombus formation, which can further obstruct blood flow and exacerbate myocardial injury (<xref ref-type="bibr" rid="B97">Takaya et al., 2005</xref>; <xref ref-type="bibr" rid="B114">Xu et al., 2006</xref>). Targeting platelet activation has shown potential in reducing the extent of myocardial damage and improving reperfusion outcomes (<xref ref-type="bibr" rid="B87">Schanze et al., 2023</xref>).</p>
<p>Collectively, the overproduction of ROS during myocardial I/R injury arises from various cellular sources, including cardiomyocytes, endothelial cells, inflammatory cells, and platelets. Functional impairment or activity changes of mitochondrial ETC, NADPH oxidase, XO and uncoupled eNOS during I/R are the core regulatory mechanisms leading to excessive ROS generation in different cell types in the injured myocardium. Understanding these sources and their mechanisms provides critical insights into the pathophysiology of MIRI. Future efforts to design ROS-responsive biomaterials should focus on targeting the specific features of excessive ROS production in the myocardial IME, with an emphasis on developing innovative biomaterials with precise cell type-specific and subcellular organelle-targeting (e.g, mitochondria) properties.</p>
</sec>
</sec>
<sec id="s3">
<title>3 Strategies for ROS-responsive biomaterials fabrication</title>
<p>The emergence and widespread application of ROS-responsive biomaterials have greatly changed the limitations of current anti-MIRI drug interventions. These advanced materials are designed to engage proactively with the pathophysiological oxidative milieu, offering a targeted and controlled release of therapeutic agents. This section delves into the mainstream strategies for the fabrication of ROS-responsive biomaterials, focusing on ROS-induced solubility switching and degradation mechanisms (<xref ref-type="table" rid="T1">Table 1</xref>).</p>
<table-wrap id="T1" position="float">
<label>TABLE 1</label>
<caption>
<p>ROS-responsive elements.</p>
</caption>
<table>
<thead valign="top">
<tr>
<th align="center">ROS-responsive mechanism</th>
<th colspan="2" align="center">ROS-responsive elements</th>
<th align="center">Chemical structure and oxidation</th>
<th align="center">Sensitivity</th>
<th align="center">References</th>
</tr>
</thead>
<tbody valign="top">
<tr>
<td rowspan="5" align="center">Solubility Switch</td>
<td rowspan="3" align="center">Sulfur-Based linkages</td>
<td align="center">Thioether</td>
<td rowspan="3" align="center">
<inline-graphic xlink:href="FBIOE_fbioe-2024-1469393_wc_tfx1.tif"/>
<break/>
<inline-graphic xlink:href="FBIOE_fbioe-2024-1469393_wc_tfx2.tif"/>
<break/>
<inline-graphic xlink:href="FBIOE_fbioe-2024-1469393_wc_tfx3.tif"/>
</td>
<td align="center">H<sub>2</sub>O<sub>2</sub>: 3.3 vol%</td>
<td rowspan="3" align="center">
<xref ref-type="bibr" rid="B33">Gruhlke and Slusarenko (2012),</xref> <xref ref-type="bibr" rid="B111">Xu et al. (2016a),</xref> <xref ref-type="bibr" rid="B104">Wang et al. (2022),</xref> <xref ref-type="bibr" rid="B126">Yue et al. (2023),</xref> <xref ref-type="bibr" rid="B116">Yang et al. (2024)</xref>
</td>
</tr>
<tr>
<td align="center">Poly (propylene sulfide)</td>
<td align="center">H<sub>2</sub>O<sub>2</sub> : 100&#xa0;&#x3bc;M</td>
</tr>
<tr>
<td align="center">Poly (L-methionine)</td>
<td align="center">H<sub>2</sub>O<sub>2</sub> : 1&#xa0;mM</td>
</tr>
<tr>
<td colspan="2" align="center">Selenium-linkages</td>
<td align="center">
<inline-graphic xlink:href="FBIOE_fbioe-2024-1469393_wc_tfx4.tif"/>
</td>
<td align="center">H<sub>2</sub>O<sub>2</sub> : 0.1% v/v</td>
<td align="center">
<xref ref-type="bibr" rid="B74">Ma et al. (2010),</xref> <xref ref-type="bibr" rid="B98">Tan et al. (2012),</xref> <xref ref-type="bibr" rid="B110">Xu et al. (2013)</xref>
</td>
</tr>
<tr>
<td colspan="2" align="center">Tellurium- linkages</td>
<td align="center">
<inline-graphic xlink:href="FBIOE_fbioe-2024-1469393_wc_tfx5.tif"/>
</td>
<td align="center">H<sub>2</sub>O<sub>2</sub> : 100&#xa0;&#x3bc;M</td>
<td align="center">
<xref ref-type="bibr" rid="B16">Cao et al. (2015),</xref> <xref ref-type="bibr" rid="B105">Wang et al. (2015)</xref>
</td>
</tr>
<tr>
<td rowspan="5" align="center">Degradation</td>
<td colspan="2" align="center">Phenylboronic Acid and Ester</td>
<td align="center">
<inline-graphic xlink:href="FBIOE_fbioe-2024-1469393_wc_tfx6.tif"/>
<break/>
<inline-graphic xlink:href="FBIOE_fbioe-2024-1469393_wc_tfx7.tif"/>
</td>
<td align="center">H<sub>2</sub>O<sub>2</sub> : 50&#xa0;&#x3bc;M</td>
<td align="center">
<xref ref-type="bibr" rid="B94">Sun et al. (2013),</xref> <xref ref-type="bibr" rid="B92">Stubelius et al. (2019),</xref> <xref ref-type="bibr" rid="B36">Han and Domaille (2022)</xref>
</td>
</tr>
<tr>
<td colspan="2" align="center">Poly (thioketal)</td>
<td align="center">
<inline-graphic xlink:href="FBIOE_fbioe-2024-1469393_wc_tfx8.tif"/>
</td>
<td align="center">H<sub>2</sub>O<sub>2</sub> : 0.2% v/v</td>
<td align="center">
<xref ref-type="bibr" rid="B67">Liu and Thayumanavan (2020),</xref> <xref ref-type="bibr" rid="B103">Wang et al. (2020),</xref> <xref ref-type="bibr" rid="B109">Xie et al. (2022),</xref> <xref ref-type="bibr" rid="B119">Yao et al. (2022b),</xref> <xref ref-type="bibr" rid="B89">Shen et al. (2024)</xref>
</td>
</tr>
<tr>
<td colspan="2" align="center">Peroxalate ester</td>
<td align="center">
<inline-graphic xlink:href="FBIOE_fbioe-2024-1469393_wc_tfx9.tif"/>
</td>
<td align="center">H<sub>2</sub>O<sub>2</sub>: &#x3e;50&#xa0;nM</td>
<td align="center">
<xref ref-type="bibr" rid="B84">Romanyuk et al. (2017)</xref>
</td>
</tr>
<tr>
<td colspan="2" align="center">Poly (L-proline)</td>
<td align="center">
<inline-graphic xlink:href="FBIOE_fbioe-2024-1469393_wc_tfx10.tif"/>
</td>
<td align="center">H<sub>2</sub>O<sub>2</sub> : 5&#xa0;mM</td>
<td align="center">
<xref ref-type="bibr" rid="B122">Yu et al. (2011),</xref> <xref ref-type="bibr" rid="B59">Lee et al. (2014),</xref> <xref ref-type="bibr" rid="B34">Gupta et al. (2015)</xref>
</td>
</tr>
<tr>
<td colspan="2" align="center">Disulfide, diselenide, and ditelluride bond</td>
<td align="center">
<inline-graphic xlink:href="FBIOE_fbioe-2024-1469393_wc_tfx11.tif"/>
<break/>
<inline-graphic xlink:href="FBIOE_fbioe-2024-1469393_wc_tfx12.tif"/>
<break/>
<inline-graphic xlink:href="FBIOE_fbioe-2024-1469393_wc_tfx13.tif"/>
</td>
<td align="center">H<sub>2</sub>O<sub>2</sub>: &#x3c;20&#xa0;&#x3bc;M</td>
<td align="center">
<xref ref-type="bibr" rid="B42">Hou et al. (2022),</xref> <xref ref-type="bibr" rid="B56">Lan et al. (2022),</xref> <xref ref-type="bibr" rid="B15">Cao et al. (2024),</xref> <xref ref-type="bibr" rid="B50">Kang et al. (2024)</xref>
</td>
</tr>
</tbody>
</table>
</table-wrap>
<sec id="s3-1">
<title>3.1 ROS-induced solubility switch</title>
<p>The principal strategy for fabricating ROS-responsive biomaterials involves the incorporation of functional groups that undergo significant solubility changes in response to ROS. Under oxidative conditions, these groups typically transform from hydrophobic to hydrophilic states, enhancing water solubility and facilitating the release of encapsulated drugs.</p>
<sec id="s3-1-1">
<title>3.1.1 Sulfur-containing polymers</title>
<p>Sulfur-containing polymers are among the earliest developed ROS-responsive systems (<xref ref-type="bibr" rid="B126">Yue et al., 2023</xref>). Due to sulfur&#x2019;s diverse oxidation states, ranging from &#x2212;2 to &#x2b;6, these materials can undergo significant changes upon exposure to ROS. When oxidized, sulfide-containing polymers form sulfoxides or sulfones, increasing their hydrophilicity. This change leads to polymer swelling, disassembly, and eventual drug release (<xref ref-type="bibr" rid="B33">Gruhlke and Slusarenko, 2012</xref>). Poly (propylene sulfide) (PPS) is the most fundamental used sulfur-containing ROS-responsive functional group. PPS-based nanoparticles, stable in water, degrade rapidly upon exposure to H<sub>2</sub>O<sub>2</sub> but not to superoxide, releasing encapsulated drugs effectively (<xref ref-type="bibr" rid="B90">Shofolawe-Bakare et al., 2022</xref>; <xref ref-type="bibr" rid="B10">Bezold et al., 2023</xref>). Thioether is another well-studied ROS-responsive linker that undergoes a hydrophobic to hydrophilic transition upon oxidation, which makes thioether-containing polymers widely used in the precise delivery and release of drugs in response to oxidative microenvironment-related diseases (<xref ref-type="bibr" rid="B104">Wang et al., 2022</xref>). Additionally, poly (L-methionine), an amino acid-based polymer, exhibits ROS-responsive behavior through the oxidation of its sulfur-containing methionine residues to sulfoxides and sulfones. This oxidation alters the polymer&#x2019;s hydrophobicity, leading to structural changes and the release of therapeutic agents (<xref ref-type="bibr" rid="B111">Xu et al., 2016a</xref>; <xref ref-type="bibr" rid="B116">Yang et al., 2024</xref>). Given the inherent advantages of this amino acid-based polymer, such as biocompatibility and biodegradability, it may become a key material in the design of next-generation therapeutics for the treatment of ROS-related diseases, such as cancer and chronic liver disease (<xref ref-type="bibr" rid="B121">Yoo et al., 2017</xref>; <xref ref-type="bibr" rid="B38">Hao Y. M. et al., 2022</xref>).</p>
</sec>
<sec id="s3-1-2">
<title>3.1.2 Selenium-containing polymers</title>
<p>Selenium-based materials exhibit a more pronounced response to ROS compared to sulfur-based ones due to selenium&#x2019;s lower electronegativity and larger atomic radius (<xref ref-type="bibr" rid="B110">Xu et al., 2013</xref>). These materials can undergo a solubility switch due to the oxidation of selenium moieties to selenoxides or selenones upon exposure to low concentrations of H<sub>2</sub>O<sub>2</sub> (0.01% v/v) (<xref ref-type="bibr" rid="B74">Ma et al., 2010</xref>), leading to the release of encapsulated therapeutic agents. The development of selenium-containing block copolymers, such as PEG-PUSe-PEG, has shown promise in drug delivery applications where the hydrophobic polyurethane block containing selenides can self-assemble into micelles that disassemble upon ROS exposure (<xref ref-type="bibr" rid="B98">Tan et al., 2012</xref>). In addition, the biological significance of selenium, particularly its role in enhancing the catalytic activity of glutathione peroxidase (GPx), makes it an ideal candidate for the design of ROS-responsive materials (<xref ref-type="bibr" rid="B51">Kieliszek and Blazejak, 2013</xref>).</p>
</sec>
<sec id="s3-1-3">
<title>3.1.3 Tellurium-containing polymers</title>
<p>Tellurium, positioned below selenium in the periodic table, offers even higher sensitivity to ROS due to its chemical properties, making tellurium-containing polymers ultra-responsive and suitable for applications in pathological microenvironment with relative low levels of ROS (<xref ref-type="bibr" rid="B16">Cao et al., 2015</xref>; <xref ref-type="bibr" rid="B105">Wang et al., 2015</xref>). Similar to selenium-based delivery systems, tellurium-containing biomaterials exhibit pronounced solubility changes under oxidative conditions (<xref ref-type="bibr" rid="B105">Wang et al., 2015</xref>), ensuring timely and controlled drug release. Their potential in therapeutic applications, particularly in inflammation and tumor progression sites (<xref ref-type="bibr" rid="B72">Lu et al., 2017</xref>; <xref ref-type="bibr" rid="B26">Dominguez-Alvarez et al., 2022</xref>), is being explored, although research in this area remains limited.</p>
</sec>
</sec>
<sec id="s3-2">
<title>3.2 ROS-induced degradation</title>
<p>Another critical strategy involves the design of biomaterials that degrade upon exposure to ROS through the cleavage of specific chemical bonds within the polymer backbone, thereby releasing the therapeutic agents in a controlled manner. This degradation mechanism is pivotal for the functionality of ROS-responsive biomaterials in targeted drug delivery and tissue engineering applications.</p>
<sec id="s3-2-1">
<title>3.2.1 Phenylboronic acid and ester-containing polymers</title>
<p>Phenylboronic acid and its ester derivatives are exceptionally sensitive to ROS, undergoing rapid oxidative degradation due to the cleavage of the boron-carbon bond (<xref ref-type="bibr" rid="B36">Han and Domaille, 2022</xref>). Under oxidizing conditions, the linkage between boronic acids/esters and the material or drug molecules of interest becomes oxidized with the insertion of oxygen (<xref ref-type="bibr" rid="B92">Stubelius et al., 2019</xref>). Notably, the reaction kinetics are significantly influenced by the nucleophilicity of the boron center, with nucleophilic boronic esters reacting more quickly than their corresponding acids (<xref ref-type="bibr" rid="B94">Sun et al., 2013</xref>). Moreover, recent studies have shown that boronic esters with ether bonds exhibit excellent degradation kinetics at biologically relevant concentrations of H<sub>2</sub>O<sub>2</sub>, around 50&#xa0;&#x3bc;M (<xref ref-type="bibr" rid="B47">Jourden et al., 2011</xref>). This sensitivity makes boronic ester-containing polymers some of the most ROS-responsive materials available, particularly suitable for applications requiring high sensitivity to ROS and precise control over the release of therapeutic agents.</p>
<p>Interestingly, most of currently reported anti-MIRI hydrogel drug delivery systems that employ ROS-responsive degradation mechanisms incorporate boronic acid or boronic ester as their core ROS-responsive functional groups (detailed in <xref ref-type="sec" rid="s4">Section 4</xref>) (<xref ref-type="bibr" rid="B65">Li et al., 2021</xref>; <xref ref-type="bibr" rid="B37">Hao T. et al., 2022</xref>; <xref ref-type="bibr" rid="B130">Zhang X. et al., 2022</xref>). This preference is likely due to their proven effectiveness in maintaining hydrogel stability while allowing for precisely controlled degradation and drug release in response to oxidative stress.</p>
</sec>
<sec id="s3-2-2">
<title>3.2.2 Poly (thioketal) (TK) polymers</title>
<p>Similar to boronic esters, thioketal linkages are destabilized in the presence of O<sub>2</sub>
<sup>&#x2022;&#x2212;</sup>and H<sub>2</sub>O<sub>2</sub>, leading to the oxidation into ketones and organic thiols or disulfides (<xref ref-type="bibr" rid="B67">Liu and Thayumanavan, 2020</xref>). This degradation mechanism has been widely used to develop ROS-responsive materials containing thioketals for targeted drug release therapy in diseases characterized by high ROS microenvironments, such as enteritis (<xref ref-type="bibr" rid="B89">Shen et al., 2024</xref>), wound repair (<xref ref-type="bibr" rid="B76">Martin et al., 2014</xref>), and ischemic heart disease (<xref ref-type="bibr" rid="B109">Xie et al., 2022</xref>; <xref ref-type="bibr" rid="B119">Yao Y. et al., 2022</xref>).</p>
</sec>
<sec id="s3-2-3">
<title>3.2.3 Peroxalate ester-containing polymers</title>
<p>Peroxalate esters are another class of ROS-responsive polymers that degrade in the presence of relative low H<sub>2</sub>O<sub>2</sub> (&#x3e;50&#xa0;nM), producing carbon dioxide and other byproducts, with the potential to generate chemiluminescence (<xref ref-type="bibr" rid="B84">Romanyuk et al., 2017</xref>; <xref ref-type="bibr" rid="B38">Hao Y. M. et al., 2022</xref>). This characteristic makes them particularly valuable in applications that benefit from real-time monitoring of ROS levels, as the chemiluminescence can serve as an optical signal for the presence of oxidative stress.</p>
<p>In the context of MIRI, peroxalate ester-containing polymers have shown potential in both diagnostic and therapeutic roles. The generated luminescent signals can help in the detection of ROS bursts during reperfusion, while the degradation of the polymer allows for the controlled release of therapeutic agents precisely when ROS levels are elevated (<xref ref-type="bibr" rid="B57">Lee D. et al., 2013</xref>). Recent advancements in the design of peroxalate ester-based hydrogels have also demonstrated their capability to act as both ROS scavengers and drug delivery platforms, thereby providing a dual function in mitigating oxidative damage and delivering cardioprotective drugs (<xref ref-type="bibr" rid="B7">Bae et al., 2016</xref>).</p>
</sec>
<sec id="s3-2-4">
<title>3.2.4 Poly (L-proline)-containing polymers</title>
<p>Poly (L-proline) is another naturally occurring amino acid-based polymer that has shown particularly sensitive to ROS due to the presence of pyrrolidine rings (<xref ref-type="bibr" rid="B101">Tian et al., 2021</xref>). Under oxidative stress, the proline residue undergoes oxidation, leading to the cleavage of the polymer backbone (<xref ref-type="bibr" rid="B4">Amici et al., 1989</xref>). This degradation results in the release of entrapped drugs or therapeutic agents, making poly (L-proline) a useful material in drug delivery systems, particularly for applications where controlled degradation is essential (<xref ref-type="bibr" rid="B25">Dai et al., 2023</xref>). Poly (L-proline) has been widely used in the fabrication of scaffolds for tissue engineering applications where the degradation rate can be matched to the tissue regeneration process (<xref ref-type="bibr" rid="B122">Yu et al., 2011</xref>; <xref ref-type="bibr" rid="B59">Lee et al., 2014</xref>). The ROS-responsiveness of these scaffolds can be further enhanced by incorporating additional ROS-sensitive elements such as boronic esters or thioketal groups.</p>
</sec>
<sec id="s3-2-5">
<title>3.2.5 Disulfide, diselenide, and ditelluride bond-bontaining polymers</title>
<p>Compared with the integration of individual chalcogen elements (sulfur, selenium, tellurium) to impart solubility transition properties to nanomaterials, recent studies have increasingly favored the use of disulfide, diselenide, and ditelluride bonds as ROS-responsive degradation elements (<xref ref-type="bibr" rid="B125">Yuan et al., 2021</xref>; <xref ref-type="bibr" rid="B42">Hou et al., 2022</xref>; <xref ref-type="bibr" rid="B56">Lan et al., 2022</xref>; <xref ref-type="bibr" rid="B106">Weng et al., 2022</xref>; <xref ref-type="bibr" rid="B80">Qiu et al., 2024</xref>). These bonds spontaneously cleave under oxidative conditions, leading to the degradation of nanomaterials and enabling controlled drug release.</p>
<p>Disulfide bond (-S-S-) is widely used due to their stability under normal conditions and their ability to break in the presence of ROS, such as H<sub>2</sub>O<sub>2</sub> (as low as 20&#xa0;&#x3bc;M), making them ideal for delivery systems for tumors and diseases related to ischemia-reperfusion injury (<xref ref-type="bibr" rid="B50">Kang et al., 2024</xref>; <xref ref-type="bibr" rid="B80">Qiu et al., 2024</xref>). Diselenide bond (-Se-Se-), with lower bond dissociation energy than disulfides, responds more quickly to ROS and have been explored in neurodegenerative diseases and MIRI (<xref ref-type="bibr" rid="B125">Yuan et al., 2021</xref>; <xref ref-type="bibr" rid="B106">Weng et al., 2022</xref>). Although less studied, the ditellurium bond (-Te-Te-) is the most sensitive to ROS and can respond rapidly, and has recently been increasingly studied for its application in nanomaterial design to alleviate diseases such as MIRI where excessive ROS production is present (<xref ref-type="bibr" rid="B42">Hou et al., 2022</xref>; <xref ref-type="bibr" rid="B56">Lan et al., 2022</xref>).</p>
</sec>
</sec>
</sec>
<sec id="s4">
<title>4 ROS-responsive therapeutic platforms for MIRI intervention</title>
<p>In recent decades, ROS-responsive functional groups have been extensively integrated into various biomaterials, such as polymer nanoparticles, hydrogels, patches, and biomimetic materials (<xref ref-type="bibr" rid="B127">Zhang et al., 2015</xref>; <xref ref-type="bibr" rid="B111">Xu et al., 2016a</xref>; <xref ref-type="bibr" rid="B18">Chakraborty et al., 2023</xref>). These advancements enable targeted and controlled drug release at sites with elevated ROS levels. Given the excessive ROS production in damaged myocardium following ischemia-reperfusion injury (<xref ref-type="bibr" rid="B14">Cadenas, 2018</xref>), recent developments in nanomedicine have increasingly utilized these ROS-responsive elements to achieve precise, targeted delivery of cardioprotective drugs with anti-inflammatory (<xref ref-type="bibr" rid="B63">Li et al., 2020</xref>; <xref ref-type="bibr" rid="B42">Hou et al., 2022</xref>; <xref ref-type="bibr" rid="B43">Huang et al., 2022</xref>; <xref ref-type="bibr" rid="B56">Lan et al., 2022</xref>; <xref ref-type="bibr" rid="B106">Weng et al., 2022</xref>), antioxidant (<xref ref-type="bibr" rid="B7">Bae et al., 2016</xref>), pro-survival (<xref ref-type="bibr" rid="B62">Li et al., 2022</xref>; <xref ref-type="bibr" rid="B130">Zhang X. et al., 2022</xref>), or pro-angiogenic properties (<xref ref-type="bibr" rid="B65">Li et al., 2021</xref>; <xref ref-type="bibr" rid="B37">Hao T. et al., 2022</xref>). By responding to ROS stimuli, these drugs can be released specifically at the site of myocardial injury, enhancing therapeutic efficacy while minimizing side effects.</p>
<p>Although several recent reviews have comprehensively explored the landscape of ROS-related nanoplatforms for alleviating MIRI, their main focus is on ROS-scavenging nanozymes and nanomaterials loaded with antioxidant drugs (<xref ref-type="bibr" rid="B131">Zhang Z. et al., 2022</xref>; <xref ref-type="bibr" rid="B64">Li et al., 2023</xref>). In contrast, here we focus on the application of various ROS-responsive biomaterials in alleviating MIRI in the past decade. Additionally, we systematically summarize the preferred ROS-responsive functional groups used in these biomaterials and highlight the cardioprotective properties of the encapsulated drugs.</p>
<sec id="s4-1">
<title>4.1 Polymeric nanoparticles</title>
<p>Biocompatible and versatile polymers such as poly (lactide-co-glycolide) (PLGA), poly (ethylene glycol) (PEG), and polyethylenimine (PEI) are commonly used to create multifunctional drug-loaded nanoparticles (<xref ref-type="bibr" rid="B85">Sah et al., 2013</xref>). To achieve ROS-responsive drug release, these nanoparticles often incorporate ROS-sensitive functional groups as linkers either between polymeric backbone chains or between the polymer and the drug molecule. Upon exposure to elevated ROS levels, these linkers undergo degradation or solubility changes, triggering the controlled release of the encapsulated drugs (<xref ref-type="bibr" rid="B112">Xu et al., 2016b</xref>). Currently, sulfide and tellurium moieties are particularly prevalent as ROS-responsive components in polymeric nanoparticles designed to selectively respond to the oxidative stress in the injured myocardium.</p>
<sec id="s4-1-1">
<title>4.1.1 Sulfide-based linkages</title>
<p>Li and colleagues have developed a ROS-responsive polymeric nanoparticle synthesized from diblock copolymers of PEG and PPS for the delivery of ginsenoside Rg3, a natural product with potent antioxidant properties, to mitigate MIRI (<xref ref-type="bibr" rid="B63">Li et al., 2020</xref>). Upon encountering ROS, the sulfide linkages within the PPS undergoes oxidative conversion from a hydrophobe to a hydrophile, releasing Rg3 specifically at the site of injury. In a rat model of MIRI, the intramyocardial injection of these nanoparticles demonstrated improved cardiac function and reduced infarct size (<xref ref-type="fig" rid="F3">Figure 3</xref>). The therapeutic action of Rg3 was found to be mediated through activating FoxO3a, a protein involved in oxidative stress regulation (<xref ref-type="bibr" rid="B66">Link, 2019</xref>).</p>
<fig id="F3" position="float">
<label>FIGURE 3</label>
<caption>
<p>ROS-responsive polymeric nanoparticles were created through the self-assembly of diblock copolymers of poly (ethylene glycol) (PEG) and poly (propylene sulfide) (PPS) and used to encapsulate and deliver Rg3 to sites of MIRI. Upon intramyocardial injection, the Rg3-loaded PEG-b-PPS nanoparticles responded to ROS, releasing Rg3, which then mitigated MIRI by interacting with FoxO3a, exerting anti-oxidative, anti-inflammatory, and anti-fibrotic effects. Reproduced with permission (<xref ref-type="bibr" rid="B63">Li et al., 2020</xref>). Copyright 2019, Elsevier.</p>
</caption>
<graphic xlink:href="fbioe-12-1469393-g003.tif"/>
</fig>
<p>Distinct from sulfide-based ROS-responsive solubility transitions, Huang et al. developed a biodegradable, redox-responsive covalent organic framework (COF) nanocarrier integrating tetraphenylethene (TPE) and disulfide moieties (ss) for prolonged MIRI therapy (<xref ref-type="bibr" rid="B43">Huang et al., 2022</xref>). The TPE-ss COF system demonstrated exceptional redox-responsiveness, degrading efficiently in the presence of H<sub>2</sub>O<sub>2</sub> and facilitating the controlled release of therapeutic agent matrine, a natural quinolizidine alkaloid that protects cells from ischemia-reperfusion injury by attenuating c-Jun N-terminal kinase (JNK) signaling. In rat models, intravenous administration of TPE-ss COF@Matrine markedly reduced myocardial infarction area, enhanced cardiac function, and alleviated myocardial fibrosis and cardiomyocyte apoptosis. Additionally, the nanocarrier exhibited prolonged retention in cardiac tissue, enabling sustained drug delivery.</p>
</sec>
<sec id="s4-1-2">
<title>4.1.2 Ditellurium linkages</title>
<p>Tellurium&#x2019;s superior responsiveness to ROS makes it a valuable component in polymeric nanoparticle design, facilitating the controlled delivery of encapsulated drugs by regulating material&#x2019;s solubility changes under oxidative conditions (<xref ref-type="bibr" rid="B16">Cao et al., 2015</xref>). For instance, Hou and colleagues have engineered an endothelial cell-targeting and ROS-ultrasensitive nanocomplex system for the co-delivery of dexamethasone (DXM) and VCAM-1 siRNA (siVCAM-1) to treat MIRI (<xref ref-type="bibr" rid="B42">Hou et al., 2022</xref>). The nanocomplexes, termed RPPT, were synthesized by crosslinking PEI with ditellurium and subsequently modified with PEG and the endothelial cell-targeting peptide cRGD (<xref ref-type="fig" rid="F4">Figure 4A</xref>). Upon systemic administration in a rat model of MIRI, the cRGD-modified nanocomplexes efficiently targeted and entered the inflamed endothelial cells located in the injured myocardium. There, RPPT was sensitively degraded by overproduced ROS, triggering the release of intracellular siVCAM-1 and DXM, thereby effectively abolishing the expression of the neutrophil recruiter VCAM-1 and inhibiting the production of proinflammatory factors such as TNF-&#x3b1;. The combined action of DXM and siVCAM-1 cooperatively inhibited both migration and adhesion of neutrophils, effectively mitigating the inflammatory response and reducing MIRI.</p>
<fig id="F4" position="float">
<label>FIGURE 4</label>
<caption>
<p>
<bold>(A)</bold> The endothelial cell-targeting, ROS-ultrasensitive NCs for co-delivery of siVCAM-1 and DXM aim to treat MIRI inflammation. The ROS-cleavable RPPT, containing ditellurium, was designed to enclose DXM-loaded PLGA NPs and siVCAM-1. After i. v. injection into rats with MIRI, RPPT@siVCAM-1 NCs efficiently targeted inflamed endothelial cells by binding to over-expressed &#x3b1;v&#x3b2;3 receptors. In the ROS-rich cytoplasm, RPPT degraded, releasing siVCAM-1, enhancing VCAM-1 silencing. This reduced neutrophil recruitment to the injured myocardium, significantly improving anti-inflammatory efficacy and myocardial function recovery. Reproduced with permission (<xref ref-type="bibr" rid="B42">Hou et al., 2022</xref>). Copyright 2022, Elsevier. <bold>(B)</bold> Cardiomyocyte-targeted nanotherapeutics for ROS-sensitive co-delivery of siRAGE and Dex were developed. Dex-loaded MSNs, coated with PPTP (a ditellurium-containing polycation), complexed with siRAGE and gated the MSNs to prevent Dex pre-leakage. After systemic injection into myocardial IR-injured rats, the nanotherapeutics entered inflamed cardiomyocytes via PGE2 recognition of over-expressed EP receptors. Intracellular ROS degraded PPTP, releasing siRAGE and Dex to silence RAGE and manage myocardial inflammation. Reproduced with permission (<xref ref-type="bibr" rid="B56">Lan et al., 2022</xref>). Copyright 2022, Tsinghua University Press.</p>
</caption>
<graphic xlink:href="fbioe-12-1469393-g004.tif"/>
</fig>
<p>Interestingly, the same research team used a similar design strategy to create an anti-inflammatory nanocomplex that specifically targets inflamed cardiomyocytes to combat MIRI (<xref ref-type="bibr" rid="B56">Lan et al., 2022</xref>). This ROS-responsive nanocomplex was synthesized by conjugating PEGylated prostaglandin E2 (PGE<sub>2</sub>-PEG) with ditellurium-crosslinked polyethyleneimine (PEI), which was then coated with DXM and loaded with receptor for advanced glycation end-products (RAGE) siRNA (siRAGE) onto mesoporous silica nanoparticles (MSNs) (<xref ref-type="fig" rid="F4">Figure 4B</xref>). The resulting nanocomplex exhibited high stability in serum, preventing premature degradation of siRNA and enabling efficient ROS-responsive release of siRAGE, achieving a 72% RAGE silencing efficiency, along with the delivery of DXM within inflamed cardiomyocytes. When administered intravenously to MIRI rats, this nanocomplex significantly reduced myocardial inflammation, leading to substantial improvements in myocardial function and reduced fibrosis.</p>
</sec>
<sec id="s4-1-3">
<title>4.1.3 Others</title>
<p>In addition to the commonly used chalcogen compounds mentioned above, peroxalate ester linkages with H&#x2082;O&#x2082; sensitivity and scavenging capabilities have been utilized to develop ROS-responsive nanoparticles for treating MIRI (<xref ref-type="bibr" rid="B7">Bae et al., 2016</xref>). Specifically, Bae and colleagues designed H&#x2082;O&#x2082;-responsive antioxidant polymer nanoparticles, known as PVAX, by incorporating peroxalate ester linkages with the naturally occurring antioxidant compound vanillyl alcohol (VA) in their backbone. These nanoparticles were synthesized using an emulsion/solvent evaporation method. The PVAX polymer rapidly degraded at sites of ROS overproduction, demonstrating superior therapeutic effects by reducing myocardial infarction size and apoptosis through its potent antioxidant properties.</p>
<p>Moreover, with the breakthrough development of fluorescent nanoprobes in the field of precise disease diagnosis, there have been continuous studies in recent years to design environmentally responsive fluorescent nanoprobes to respond to specific stimuli (such as ROS) to achieve simultaneous high-contrast imaging and targeted treatment of lesion areas (<xref ref-type="bibr" rid="B88">Shen et al., 2021</xref>; <xref ref-type="bibr" rid="B113">Xu et al., 2022</xref>; <xref ref-type="bibr" rid="B69">Liu J. et al., 2023</xref>; <xref ref-type="bibr" rid="B93">Sun et al., 2023</xref>). For example, in the study of Ziegler et al., a self-assembled fluorescent nanoprobe was developed for imaging and therapy of MIRI. This nanoprobe is composed of an amphiphilic copolymer that incorporates a hydrophilic chain of PEG and hydrophobic components of luminol-conjugated chlorin e6 (Ce6) (<xref ref-type="bibr" rid="B135">Ziegler et al., 2019</xref>). The unique design allows the nanoprobe to self-assemble into nanoparticles that can specifically target areas of injured myocardium due to the local increase in ROS. The nanoprobe demonstrated high specificity for the ischemic/reperfused myocardium with fluorescence signals up to 24&#xa0;h post reperfusion in a mouse model of myocardial I/R. Moreover, this study further discusses the broader implications of using ROS-responsive nanoprobe for targeted drug delivery in other ROS-associated conditions such as stroke, renal infarction, and inflammatory diseases. This dual functionality-imaging and therapy-makes fluorescent nanoprobes an attractive platform for the development of theranostics, which combine diagnostics with therapy.</p>
</sec>
</sec>
<sec id="s4-2">
<title>4.2 Injectable hydrogels</title>
<p>Hydrogels are high molecular weight polymer materials with a three-dimensional cross-linked network structure, known for their exceptional water absorption and swelling properties, making them excellent drug delivery carriers (<xref ref-type="bibr" rid="B35">Hamidi et al., 2008</xref>). Injectable hydrogels, in particular, have emerged as a versatile platform in nanomedicine, offering several advantages in drug delivery and tissue engineering (<xref ref-type="bibr" rid="B6">Bae et al., 2013</xref>). They can facilitate local treatment through minimally invasive administration, reducing systemic side effects and improving patient compliance. These hydrogels can be engineered to respond to specific microenvironmental triggers, such as pH, temperature, and oxidative stress, allowing for precise control of drug release and enhancing therapeutic efficacy (<xref ref-type="bibr" rid="B1">Abdollahiyan et al., 2020</xref>).</p>
<p>By taking advantage of the high concentration of ROS in the damaged myocardium after I/R, in recent years, there have been continuous studies on the development of ROS-responsive hydrogels to achieve precise targeting and sustained release of drugs by intramyocardial or intrapericardial injection in the damaged area (<xref ref-type="bibr" rid="B65">Li et al., 2021</xref>; <xref ref-type="bibr" rid="B37">Hao T. et al., 2022</xref>; <xref ref-type="bibr" rid="B130">Zhang X. et al., 2022</xref>). These hydrogel designs all use similar ROS-responsive degradation elements, namely boronic acid/ester functional groups. The preference for boronic acid/ester as ROS-responsive elements in hydrogel design may stem from their stability under normal physiological conditions but superior reactivity to elevated ROS levels and ability to undergo rapid degradation to facilitate the precise release of encapsulated therapeutic agents in the injured myocardium.</p>
<p>For example, Li and colleagues have engineered a ROS-responsive hydrogel loaded with basic fibroblast growth factor (bFGF) for myocardial repair following I/R injury (<xref ref-type="bibr" rid="B65">Li et al., 2021</xref>). This innovative hydrogel was synthesized from poly (vinyl alcohol) (PVA) cross-linked with a ROS-sensitive benzoboric acid derivative, enabling the delivery of bFGF directly to the heart&#x2019;s surface upon injection into the pericardial cavity (iPC) (<xref ref-type="fig" rid="F5">Figure 5A</xref>). This design takes advantage of the elevated ROS levels in the damaged myocardium to trigger &#x201c;on-demand&#x201d; release of bFGF, thereby facilitating angiogenesis and enhancing cardiac function in a rat model of I/R injury (<xref ref-type="fig" rid="F5">Figure 5B</xref>). Most importantly, these researchers also proved the feasibility of minimally invasive iPC access in a human patient during a standard LARIAT procedure, highlighting the potential for clinical translation (<xref ref-type="fig" rid="F5">Figure 5C</xref>).</p>
<fig id="F5" position="float">
<label>FIGURE 5</label>
<caption>
<p>
<bold>(A)</bold> Schematic illustration of Gel-bFGF fabrication and overall strategy. <bold>(B)</bold> Quantitative data corresponding to ki67, vWF CD 31 staining showed that Gel-bFGF injection promoted angiomyogenesis. <bold>(C)</bold> A schematic illustrating minimally invasive iPC access in human patients alongside fluoroscopy images from a patient who underwent a LARIAT procedure. Reproduced with permission (<xref ref-type="bibr" rid="B65">Li et al., 2021</xref>). Copyright 2021, Wiley. <bold>(D)</bold> Schematic illustration of the treatment of I/R heart injury by CS-B-NO. <bold>(E)</bold> Schematic illustration summarizing the mechanism of CS-B-NO hydrogel on inhibiting the NF-&#x1d705;B signaling pathway after I/R injury. <bold>(F)</bold> Schematic illustration summarizing the mechanism of CS-B-NO hydrogel on activation of the Nrf2 pathway agains oxidative stress via enhancing Keap1 S-nitrosylation. Reproduced with permission (<xref ref-type="bibr" rid="B37">Hao T. et al., 2022</xref>). Copyright 2022, Wiley.</p>
</caption>
<graphic xlink:href="fbioe-12-1469393-g005.tif"/>
</fig>
<p>Similarly, Hao and colleagues utilized boronic ester as ROS-responsive element to fabricate an innovative, injectable dual-function hydrogel, CS-B-NO, designed to counteract MIRI by addressing the ROS/NO disequilibrium (<xref ref-type="bibr" rid="B37">Hao T. et al., 2022</xref>). This hydrogel, synthesized from chitosan modified with boronate-protected diazeniumdiolate, stands out for its ability to release NO in response to ROS stimulation, thereby modulating the ROS/NO imbalance post-I/R injury (<xref ref-type="fig" rid="F5">Figure 5D</xref>). The CS-B-NO hydrogel exhibited significant therapeutic effects in attenuating cardiac injury and adverse cardiac remodeling in a mouse model of MIRI. The underlying mechanism involved the activation of the antioxidant defense system and protection against oxidative stress induced by I/R injury through the adaptive regulation of the Nrf2-Keap1 pathway, leading to a reduction in inflammation by inhibiting the activation of NF-&#x3ba;B signaling (<xref ref-type="bibr" rid="B9">Bellezza et al., 2018</xref>).</p>
<p>In addition, Zhang and colleagues have devised a hierarchical targeting pH and ROS dual-responsive hydrogel system that aimed to restore mitochondrial function and alleviate oxidative stress (<xref ref-type="bibr" rid="B130">Zhang X. et al., 2022</xref>). Notably, this system utilized both thioketal and boronic ester linkages known for their ROS-responsive degradation properties. Initially, mitochondrial-targeting polymeric micelles (PTPSC) were constructed, which self-assemble from thioketal-crosslinked PLGA and PEG (PLGA-TK-PEG) modified with the mitochondrial-targeting Szeto-Schiller (SS31) peptide. Subsequently, these PTPSC micelles were encapsulated within a pH/ROS dual-responsive injectable hydrogel crosslinked by reversible imine and boronic ester bonds, and loaded with cyclosporine A (CsA), a well-established drug known to inhibit the opening of the mitochondrial permeability transition pore (mPTP). In response to the low pH and high ROS in cardiac tissue during reperfusion, the imine and boronate bonds in the hydrogels were broken and the CsA-loaded PTPSCs were controllably released from the hydrogel matrix into damaged cardiomyocytes (<xref ref-type="fig" rid="F6">Figure 6</xref>). The elevated intracellular ROS further induced the cleavage of the thioketal linker and targeted the release of CsA into the mitochondria via SS31 peptide, thereby blocking the opening of the mPTP and inhibiting mitochondria-mediated cardiomyocyte apoptosis, while attenuating the output of mitochondrial ROS to reduce cytoplasmic ROS levels. In rat models, this novel smart hydrogel system demonstrated remarkable therapeutic efficacy by restoring mitochondrial and cardiac functions, underscoring its potent ROS scavenging capabilities and innovative contribution to cardiac repair. The integration of these state of the art biomaterials and mechanisms underscores a promising approach for targeted therapy, especially in mitigating oxidative stress-related pathologies where mitochondrial dysfunction plays a pivotal role.</p>
<fig id="F6" position="float">
<label>FIGURE 6</label>
<caption>
<p>Schematic illustrating the preparation of ROS-responsive, mitochondria-targeted nanomicelles encapsulating CsA, and the construction of a pH/ROS dually responsive CsA nanomicelle-loaded injectable hydrogel using Schiff base reactions and boronic ester bonding crosslinks. In a rat model of myocardial ischemia-reperfusion injury, this hydrogel ensures precise delivery of nanodrugs to mitochondria in response to low pH and high ROS, reducing oxidative stress at microenvironmental, cellular, and subcellular levels, and restoring mitochondrial and myocardial functions. Reproduced with permission (<xref ref-type="bibr" rid="B130">Zhang X. et al., 2022</xref>). Copyright 2022, Elsevier.</p>
</caption>
<graphic xlink:href="fbioe-12-1469393-g006.tif"/>
</fig>
</sec>
<sec id="s4-3">
<title>4.3 Biomimetic biomaterials</title>
<p>Given the remarkable biocompatibility, low immunogenicity, and low toxicity of biomimetic nanomaterials that incorporate cells, cellular components (such as membranes, lipoproteins, etc.), and extracellular vesicles (EVs), biomimetic nanomaterials have emerged as a prominent strategy in nanomedicine development (<xref ref-type="bibr" rid="B115">Yaman et al., 2020</xref>). In the treatment of ischemic heart disease, this biomimetic approach enables nanomaterials to disguise themselves as endogenous substances and target damaged myocardial areas, thereby minimizing toxicity and enhancing biocompatibility (<xref ref-type="bibr" rid="B55">Laiva et al., 2015</xref>; <xref ref-type="bibr" rid="B49">Kang and Kwon, 2022</xref>). A recent systematic review comprehensively summarized the research progress on biomimetic nanomaterials based on different cell types of biomembranes and EVs for ischemic heart disease therapy (<xref ref-type="bibr" rid="B123">Yu et al., 2024</xref>). Notably, in recent years, research has focused on integrating various microenvironmental responsive elements into these biomimetic nanodelivery platforms to improve their drug loading targeting and controlled release capabilities (<xref ref-type="bibr" rid="B83">Rios et al., 2015</xref>; <xref ref-type="bibr" rid="B107">Wu et al., 2016</xref>; <xref ref-type="bibr" rid="B53">Kobayashi et al., 2018</xref>; <xref ref-type="bibr" rid="B68">Liu et al., 2019</xref>). In studies on alleviating MIRI, to date, only two study has used ROS-responsive polymeric materials to load anti-inflammatory and pro-suvival drugs and integrated them into platelet membrane chimeric nanodelivery system to achieve targeted drug delivery in damaged myocardium (<xref ref-type="bibr" rid="B62">Li et al., 2022</xref>; <xref ref-type="bibr" rid="B106">Weng et al., 2022</xref>).</p>
<p>Specifically, Weng and colleagues developed this innovative platelet-bionic ROS-responsive delivery platform, PLP-RvD1, utilizing platelet membrane chimerism modified liposomes to achieve targeted delivery to myocardial macrophages at the injury site and mediate ROS-responsive release of the anti-inflammatory drug Resolvin D1 via diselenide bonds (<xref ref-type="fig" rid="F7">Figure 7A</xref>) (<xref ref-type="bibr" rid="B106">Weng et al., 2022</xref>). In a mouse MIRI model, the intravenous injection of PLP-RvD1 resulted in the enrichment of RvD1 in the injured myocardium, promoting macrophage efferocytosis of apoptotic cardiomyocytes, production of specialized proresolving mediators (SPMs), and angiogenesis during injury repair process, effectively improving ventricular remodeling and protecting cardiac function. Furthermore, biosafety assessment of this delivery system demonstrated that PLP-RvD1 did not induce acute inflammatory responses, exhibited no potential immune reactions, and lacked organ toxicity, suggesting its suitability for potential clinical applications.</p>
<fig id="F7" position="float">
<label>FIGURE 7</label>
<caption>
<p>
<bold>(A)</bold> A delivery platform called PLP-RvD1, which is responsive to ROS and mimics platelets, was designed. It is created by combining ROS-responsive liposomes loaded with RvD1 and platelet membranes. This platform retains the platelets&#x2019; ability to interact with monocytes, allowing it to reach cardiac injury sites by hitching a ride with chemotactic circulating monocytes following intravenous injection. The high levels of ROS at the injury site break down the platform, releasing RvD1 quickly. The released RvD1 then facilitates the clearance of dead cardiomyocytes, the production of SPMs, and angiogenesis, which helps improve ventricular remodeling and maintain cardiac function in mice with myocardial I/R injury. Reproduced with permission (<xref ref-type="bibr" rid="B106">Weng et al., 2022</xref>). Copyright 2022, BioMed Central. <bold>(B)</bold> CsA@PPTK effectively accumulated in the ischemic myocardium of MI/RI mice, where it significantly reduced ROS and promoted the generation of Tregs while increasing the ratio of M2 to M1 macrophages. Additionally, CsA@PPTK notably decreased cardiomyocyte apoptosis, reduced infarct size and fibrosis in the ischemic myocardium, and lowered MMP-9 protein expression while increasing CX43 protein expression in the affected tissue. These effects led to a substantial reduction in left ventricular remodeling and a marked improvement in heart function in MI/RI mice. Copyright 2022, BioMed Central.</p>
</caption>
<graphic xlink:href="fbioe-12-1469393-g007.tif"/>
</fig>
<p>Similarly, Li and colleagues employed a biomimetic strategy to develop a platelet membrane-cloaked nanoparticle, CsA@PPTK (<xref ref-type="fig" rid="F7">Figure 7B</xref>). This nanoparticle is constructed using poly (thioketal) (PTK), a material rich in thioketal bonds that are sensitive to various types of ROS. The ROS sensitivity allows the nanoparticle to release its encapsulated anti-apoptotic drug, CsA, specifically at the site of injury where ROS levels are elevated (<xref ref-type="bibr" rid="B62">Li et al., 2022</xref>). Upon intravenous injection, CsA@PPTK effectively accumulated in the infarcted myocardium of MIRI mice, where it scavenged ROS and modulated the inflammatory response. This modulation was achieved by increasing the generation of regulatory T cells (Tregs) and enhancing the M2/M1 macrophage ratio. As a result, this targeted delivery and responsive release strategy significantly reduced cardiomyocyte apoptosis, decreased infarct size, and mitigated fibrosis, leading to improved cardiac function and left ventricular remodeling. Furthermore, biosafety assessments revealed that CsA@PPTK did not induce acute inflammation, immune reactions, or organ toxicity, highlighting its potential as a promising candidate for clinical applications in treating MIRI.</p>
<p>In addition to the above-mentioned ROS-responsive therapeutic platforms specifically designed for MIRI, recent studies have also extensively explored ROS-responsive nanomaterials with nearly identical design principles, including the same ROS-responsive elements and material types, for the treatment of myocardial infarction (MI). These nanomaterials are often loaded with drugs that possess anti-inflammatory, antioxidant, pro-angiogenic, and anti-fibrotic properties (<xref ref-type="bibr" rid="B118">Yao M. Y. et al., 2022</xref>; <xref ref-type="bibr" rid="B133">Zheng et al., 2022b</xref>; <xref ref-type="bibr" rid="B45">Ji et al., 2023</xref>; <xref ref-type="bibr" rid="B95">Sun et al., 2024</xref>; <xref ref-type="bibr" rid="B129">Zhang J. H. et al., 2024</xref>). Given the close similarities in the pathological processes underlying MI and MIRI, it is highly probable that the nanomedicines developed for MI could also yield significant therapeutic benefits in the treatment of MIRI. Notably, while ROS-responsive nanomaterials carrying anti-fibrotic agents have been effectively utilized in MI therapy (<xref ref-type="bibr" rid="B45">Ji et al., 2023</xref>; <xref ref-type="bibr" rid="B95">Sun et al., 2024</xref>), they have not yet been applied in the context of MIRI treatment. The future development of anti-MIRI nanomedicine may need to adopt a more holistic approach. This would involve integrating a spectrum of cardioprotective drugs with multiple therapeutic properties, aimed at providing comprehensive protection of cardiac structure and function throughout the disease progression, from acute injury to chronic remodeling.</p>
</sec>
</sec>
<sec id="s5">
<title>5 Prospects and conclusion</title>
<p>ROS overproduction during I/R play a crucial role in myocardial injury, presenting both a challenge and an opportunity for innovative treatment strategies. ROS-responsive biomaterials have emerged as a promising approach to addressing I/R injury in the heart as well as other organs such as liver, kidney and brain. Despite their potential, several challenges must be overcome to translate these biomaterials from the laboratory to clinical practice. 1) One significant challenge is the integration of multifunctionality in current ROS-responsive biomaterials to address both diagnostic and therapeutic needs. The ability to combine therapy with real-time imaging could significantly improve monitoring and treatment precision for MIRI. Furthermore, integrating multiple therapeutic modalities such as antioxidant, anti-inflammatory, pro-angiogenic, and anti-fibrotic therapies may produce synergistic effects, thereby enhancing myocardial recovery and function. 2) Another critical challenge is the complexity of the myocardial I/R microenvironment, characterized by fluctuating ROS levels and diverse pathological features that vary depending on the extent of myocardial injury in each patient. This variability directly impacts the efficacy of nanomaterials. To overcome this, it is crucial to enhance our understanding of ROS biology, focusing on the spatiotemporal changes of ROS in the myocardium after I/R. Future designs should also integrate multi-stimulus-responsive capabilities that can react to additional I/R markers such as pH and inflammation. This strategy will facilitate the creation of smart-responsive systems that can dynamically adapt to these microenvironmental changes, thereby enhancing targeting precision and therapeutic efficacy. 3) With the exception of <italic>in situ</italic> injected biomaterials, such as hydrogels, current therapeutic polymeric or biomimetic nanoparticles injected intravenously are difficult to effectively target to the heart and are often cleared by the liver or kidneys. Therefore, the design of these materials should also incorporate strategies that enhance their affinity and retention within the damaged myocardium, possibly through the use of heart-specific peptides or antibodies. 4) Addressing the biosafety and systemic toxicity of these advanced materials is paramount. Although nanomedicine can enhance drug bioavailability and prolong circulation times, the long-term effects require thorough investigation. Understanding the pharmacokinetics, biodegradation, and metabolic profiles of these materials is essential to ensuring their safe clinical application. Preclinical studies and clinical trials should explore the efficacy of these nanomaterials in larger animal models to better evaluate their clinical potential. A focus on rigorous preclinical testing and streamlined regulatory processes will also be essential to facilitate the transition from bench to bedside. 5) Finally, the scalability of production is another hurdle that must be overcome. As these biomaterials move towards clinical application, the need for efficient manufacturing processes that maintain material integrity and functionality at scale becomes evident. This is crucial for meeting the demands of clinical practice while ensuring cost-effectiveness.</p>
<p>In conclusion, significant advances in ROS-responsive biomaterials, including polymeric nanoparticles, hydrogels, and biomimetic nanomaterials, offer a promising approach to treating ischemia-reperfusion injuries by enabling targeted therapeutic delivery. These biomaterials can reduce myocardial damage more effectively than current therapeutics, but challenges remain in patient variability, targeting specificity, biocompatibility, long-term safety and efficacy, and manufacturing scalability. Continued research focusing on these areas is crucial. By addressing these challenges, ROS-responsive biomaterials could revolutionize the management of ischemic conditions across multiple organ systems, significantly improving patient outcomes and paving the way for personalized medical interventions.</p>
</sec>
</body>
<back>
<sec id="s6">
<title>Author contributions</title>
<p>YZ: Visualization, Writing&#x2013;original draft, Writing&#x2013;review and editing, Investigation. MJ: Investigation, Visualization, Writing&#x2013;original draft. TW: Conceptualization, Funding acquisition, Investigation, Supervision, Visualization, Writing&#x2013;original draft, Writing&#x2013;review and editing.</p>
</sec>
<sec sec-type="funding-information" id="s7">
<title>Funding</title>
<p>The author(s) declare that financial support was received for the research, authorship, and/or publication of this article. This work was funded by grant 82000266 form the National Natural Science Foundation of China (to TW).</p>
</sec>
<sec sec-type="COI-statement" id="s8">
<title>Conflict of interest</title>
<p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p>
</sec>
<sec sec-type="disclaimer" id="s9">
<title>Publisher&#x2019;s note</title>
<p>All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.</p>
</sec>
<ref-list>
<title>References</title>
<ref id="B1">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Abdollahiyan</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Baradaran</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>De La Guardia</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Oroojalian</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Mokhtarzadeh</surname>
<given-names>A.</given-names>
</name>
</person-group> (<year>2020</year>). <article-title>Cutting-edge progress and challenges in stimuli responsive hydrogel microenvironment for success in tissue engineering today</article-title>. <source>J. Control Release</source> <volume>328</volume>, <fpage>514</fpage>&#x2013;<lpage>531</lpage>. <pub-id pub-id-type="doi">10.1016/j.jconrel.2020.09.030</pub-id>
</citation>
</ref>
<ref id="B2">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Algoet</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Janssens</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Himmelreich</surname>
<given-names>U.</given-names>
</name>
<name>
<surname>Gsell</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Pusovnik</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Van Den Eynde</surname>
<given-names>J.</given-names>
</name>
<etal/>
</person-group> (<year>2023</year>). <article-title>Myocardial ischemia-reperfusion injury and the influence of inflammation</article-title>. <source>Trends Cardiovasc Med.</source> <volume>33</volume>, <fpage>357</fpage>&#x2013;<lpage>366</lpage>. <pub-id pub-id-type="doi">10.1016/j.tcm.2022.02.005</pub-id>
</citation>
</ref>
<ref id="B3">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Alkaitis</surname>
<given-names>M. S.</given-names>
</name>
<name>
<surname>Crabtree</surname>
<given-names>M. J.</given-names>
</name>
</person-group> (<year>2012</year>). <article-title>Recoupling the cardiac nitric oxide synthases: tetrahydrobiopterin synthesis and recycling</article-title>. <source>Curr. Heart Fail Rep.</source> <volume>9</volume>, <fpage>200</fpage>&#x2013;<lpage>210</lpage>. <pub-id pub-id-type="doi">10.1007/s11897-012-0097-5</pub-id>
</citation>
</ref>
<ref id="B4">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Amici</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Levine</surname>
<given-names>R. L.</given-names>
</name>
<name>
<surname>Tsai</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Stadtman</surname>
<given-names>E. R.</given-names>
</name>
</person-group> (<year>1989</year>). <article-title>Conversion of amino acid residues in proteins and amino acid homopolymers to carbonyl derivatives by metal-catalyzed oxidation reactions</article-title>. <source>J. Biol. Chem.</source> <volume>264</volume>, <fpage>3341</fpage>&#x2013;<lpage>3346</lpage>. <pub-id pub-id-type="doi">10.1016/s0021-9258(18)94071-8</pub-id>
</citation>
</ref>
<ref id="B5">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Antoniades</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Shirodaria</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Warrick</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Cai</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>De Bono</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>J.</given-names>
</name>
<etal/>
</person-group> (<year>2006</year>). <article-title>5-methyltetrahydrofolate rapidly improves endothelial function and decreases superoxide production in human vessels: effects on vascular tetrahydrobiopterin availability and endothelial nitric oxide synthase coupling</article-title>. <source>Circulation</source> <volume>114</volume>, <fpage>1193</fpage>&#x2013;<lpage>1201</lpage>. <pub-id pub-id-type="doi">10.1161/circulationaha.106.612325</pub-id>
</citation>
</ref>
<ref id="B6">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bae</surname>
<given-names>K. H.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>L. S.</given-names>
</name>
<name>
<surname>Kurisawa</surname>
<given-names>M.</given-names>
</name>
</person-group> (<year>2013</year>). <article-title>Injectable biodegradable hydrogels: progress and challenges</article-title>. <source>J. Mater Chem. B</source> <volume>1</volume>, <fpage>5371</fpage>&#x2013;<lpage>5388</lpage>. <pub-id pub-id-type="doi">10.1039/c3tb20940g</pub-id>
</citation>
</ref>
<ref id="B7">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bae</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Park</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Kang</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Dilmen</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Kang</surname>
<given-names>T. H.</given-names>
</name>
<name>
<surname>Kang</surname>
<given-names>D. G.</given-names>
</name>
<etal/>
</person-group> (<year>2016</year>). <article-title>Hydrogen peroxide-responsive nanoparticle reduces myocardial ischemia/reperfusion injury</article-title>. <source>J. Am. Heart Assoc.</source> <volume>5</volume>, <fpage>e003697</fpage>. <pub-id pub-id-type="doi">10.1161/jaha.116.003697</pub-id>
</citation>
</ref>
<ref id="B8">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Begonja</surname>
<given-names>A. J.</given-names>
</name>
<name>
<surname>Gambaryan</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Geiger</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Aktas</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Pozgajova</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Nieswandt</surname>
<given-names>B.</given-names>
</name>
<etal/>
</person-group> (<year>2005</year>). <article-title>Platelet NAD(P)H-oxidase&#x2013;generated ROS production regulates &#x3b1;IIb&#x3b2;3-integrin activation independent of the NO/cGMP pathway</article-title>. <source>Blood</source> <volume>106</volume>, <fpage>2757</fpage>&#x2013;<lpage>2760</lpage>. <pub-id pub-id-type="doi">10.1182/blood-2005-03-1047</pub-id>
</citation>
</ref>
<ref id="B9">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bellezza</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Giambanco</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Minelli</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Donato</surname>
<given-names>R.</given-names>
</name>
</person-group> (<year>2018</year>). <article-title>Nrf2-Keap1 signaling in oxidative and reductive stress</article-title>. <source>Biochim. Biophys. Acta Mol. Cell Res.</source> <volume>1865</volume>, <fpage>721</fpage>&#x2013;<lpage>733</lpage>. <pub-id pub-id-type="doi">10.1016/j.bbamcr.2018.02.010</pub-id>
</citation>
</ref>
<ref id="B10">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bezold</surname>
<given-names>M. G.</given-names>
</name>
<name>
<surname>Hanna</surname>
<given-names>A. R.</given-names>
</name>
<name>
<surname>Dollinger</surname>
<given-names>B. R.</given-names>
</name>
<name>
<surname>Patil</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Yu</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Duvall</surname>
<given-names>C. L.</given-names>
</name>
<etal/>
</person-group> (<year>2023</year>). <article-title>Hybrid shear-thinning hydrogel integrating hyaluronic acid with ROS-responsive nanoparticles</article-title>. <source>Adv. Funct. Mater</source> <volume>33</volume>, <fpage>2213368</fpage>. <pub-id pub-id-type="doi">10.1002/adfm.202213368</pub-id>
</citation>
</ref>
<ref id="B11">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Boueiz</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Damarla</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Hassoun</surname>
<given-names>P. M.</given-names>
</name>
</person-group> (<year>2008</year>). <article-title>Xanthine oxidoreductase in respiratory and cardiovascular disorders</article-title>. <source>Am. J. Physiol. Lung Cell Mol. Physiol.</source> <volume>294</volume>, <fpage>L830</fpage>&#x2013;<lpage>L840</lpage>. <pub-id pub-id-type="doi">10.1152/ajplung.00007.2008</pub-id>
</citation>
</ref>
<ref id="B12">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Braunersreuther</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Montecucco</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Asrih</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Pelli</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Galan</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Frias</surname>
<given-names>M.</given-names>
</name>
<etal/>
</person-group> (<year>2013</year>). <article-title>Role of NADPH oxidase isoforms NOX1, NOX2 and NOX4 in myocardial ischemia/reperfusion injury</article-title>. <source>J. Mol. Cell Cardiol.</source> <volume>64</volume>, <fpage>99</fpage>&#x2013;<lpage>107</lpage>. <pub-id pub-id-type="doi">10.1016/j.yjmcc.2013.09.007</pub-id>
</citation>
</ref>
<ref id="B13">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bugger</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Pfeil</surname>
<given-names>K.</given-names>
</name>
</person-group> (<year>2020</year>). <article-title>Mitochondrial ROS in myocardial ischemia reperfusion and remodeling</article-title>. <source>Biochim. Biophys. Acta Mol. Basis Dis.</source> <volume>1866</volume>, <fpage>165768</fpage>. <pub-id pub-id-type="doi">10.1016/j.bbadis.2020.165768</pub-id>
</citation>
</ref>
<ref id="B14">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cadenas</surname>
<given-names>S.</given-names>
</name>
</person-group> (<year>2018</year>). <article-title>ROS and redox signaling in myocardial ischemia-reperfusion injury and cardioprotection</article-title>. <source>Free Radic. Biol. Med.</source> <volume>117</volume>, <fpage>76</fpage>&#x2013;<lpage>89</lpage>. <pub-id pub-id-type="doi">10.1016/j.freeradbiomed.2018.01.024</pub-id>
</citation>
</ref>
<ref id="B15">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cao</surname>
<given-names>B. J.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>H. Y.</given-names>
</name>
<name>
<surname>Sun</surname>
<given-names>M. Z.</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>C. L.</given-names>
</name>
<name>
<surname>Kuang</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>L. G.</given-names>
</name>
</person-group> (<year>2024</year>). <article-title>Chiral MoSe2 nanoparticles for ultrasensitive monitoring of reactive oxygen species <italic>in vivo</italic>
</article-title>. <source>Adv. Mater.</source> <volume>36</volume>, <fpage>e2208037</fpage>. <pub-id pub-id-type="doi">10.1002/adma.202208037</pub-id>
</citation>
</ref>
<ref id="B16">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cao</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Gu</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>H.</given-names>
</name>
</person-group> (<year>2015</year>). <article-title>Ultra-sensitive ROS-responsive tellurium-containing polymers</article-title>. <source>Chem. Commun. (Camb)</source> <volume>51</volume>, <fpage>7069</fpage>&#x2013;<lpage>7071</lpage>. <pub-id pub-id-type="doi">10.1039/c5cc01779c</pub-id>
</citation>
</ref>
<ref id="B17">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chakraborti</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Mandal</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Mandal</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Das</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Chakraborti</surname>
<given-names>S.</given-names>
</name>
</person-group> (<year>2000</year>). <article-title>Complement activation in heart diseases</article-title>. <source>Cell Signal</source> <volume>12</volume>, <fpage>607</fpage>&#x2013;<lpage>617</lpage>. <pub-id pub-id-type="doi">10.1016/s0898-6568(00)00111-x</pub-id>
</citation>
</ref>
<ref id="B18">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chakraborty</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Alexander</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Luo</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Al&#x2010;Salam</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Van Oirschot</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Ranganath</surname>
<given-names>S. H.</given-names>
</name>
<etal/>
</person-group> (<year>2023</year>). <article-title>Engineering multifunctional adhesive hydrogel patches for biomedical applications</article-title>. <source>Interdiscip. Med.</source> <volume>1</volume>. <pub-id pub-id-type="doi">10.1002/inmd.20230008</pub-id>
</citation>
</ref>
<ref id="B19">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chen</surname>
<given-names>G. H.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>Y. J.</given-names>
</name>
<name>
<surname>Tang</surname>
<given-names>R. J.</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>C. R.</given-names>
</name>
</person-group> (<year>2019</year>). <article-title>Activation of mir-145/P70s6k1/enos pathway in microvascular endothelial cells by tongxinluo alleviates myocardial ischemia/reperfusion injury-role of exosomal linc-ror from cardiomyocytes</article-title>. <source>J. Am. Coll. Cardiol.</source> <volume>73</volume>, <fpage>46</fpage>. <pub-id pub-id-type="doi">10.1016/s0735-1097(19)30655-2</pub-id>
</citation>
</ref>
<ref id="B20">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chen</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Moghaddas</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Hoppel</surname>
<given-names>C. L.</given-names>
</name>
<name>
<surname>Lesnefsky</surname>
<given-names>E. J.</given-names>
</name>
</person-group> (<year>2008</year>). <article-title>Ischemic defects in the electron transport chain increase the production of reactive oxygen species from isolated rat heart mitochondria</article-title>. <source>Am. J. Physiol. Cell Physiol.</source> <volume>294</volume>, <fpage>C460</fpage>&#x2013;<lpage>C466</lpage>. <pub-id pub-id-type="doi">10.1152/ajpcell.00211.2007</pub-id>
</citation>
</ref>
<ref id="B21">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chen</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Duan</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Diao</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Liang</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>H.</given-names>
</name>
<etal/>
</person-group> (<year>2021</year>). <article-title>ROS-responsive capsules engineered from EGCG-Zinc networks improve therapeutic angiogenesis in mouse limb ischemia</article-title>. <source>Bioact. Mater</source> <volume>6</volume>, <fpage>1</fpage>&#x2013;<lpage>11</lpage>. <pub-id pub-id-type="doi">10.1016/j.bioactmat.2020.07.013</pub-id>
</citation>
</ref>
<ref id="B22">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chouchani</surname>
<given-names>E. T.</given-names>
</name>
<name>
<surname>Pell</surname>
<given-names>V. R.</given-names>
</name>
<name>
<surname>Gaude</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Aksentijevic</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Sundier</surname>
<given-names>S. Y.</given-names>
</name>
<name>
<surname>Robb</surname>
<given-names>E. L.</given-names>
</name>
<etal/>
</person-group> (<year>2014</year>). <article-title>Ischaemic accumulation of succinate controls reperfusion injury through mitochondrial ROS</article-title>. <source>Nature</source> <volume>515</volume>, <fpage>431</fpage>&#x2013;<lpage>435</lpage>. <pub-id pub-id-type="doi">10.1038/nature13909</pub-id>
</citation>
</ref>
<ref id="B23">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chouchani</surname>
<given-names>E. T.</given-names>
</name>
<name>
<surname>Pell</surname>
<given-names>V. R.</given-names>
</name>
<name>
<surname>James</surname>
<given-names>A. M.</given-names>
</name>
<name>
<surname>Work</surname>
<given-names>L. M.</given-names>
</name>
<name>
<surname>Saeb-Parsy</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Frezza</surname>
<given-names>C.</given-names>
</name>
<etal/>
</person-group> (<year>2016</year>). <article-title>A unifying mechanism for mitochondrial superoxide production during ischemia-reperfusion injury</article-title>. <source>Cell Metab.</source> <volume>23</volume>, <fpage>254</fpage>&#x2013;<lpage>263</lpage>. <pub-id pub-id-type="doi">10.1016/j.cmet.2015.12.009</pub-id>
</citation>
</ref>
<ref id="B24">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chung</surname>
<given-names>M. F.</given-names>
</name>
<name>
<surname>Chia</surname>
<given-names>W. T.</given-names>
</name>
<name>
<surname>Wan</surname>
<given-names>W. L.</given-names>
</name>
<name>
<surname>Lin</surname>
<given-names>Y. J.</given-names>
</name>
<name>
<surname>Sung</surname>
<given-names>H. W.</given-names>
</name>
</person-group> (<year>2015</year>). <article-title>Controlled release of an anti-inflammatory drug using an ultrasensitive ROS-responsive gas-generating carrier for localized inflammation inhibition</article-title>. <source>J. Am. Chem. Soc.</source> <volume>137</volume>, <fpage>12462</fpage>&#x2013;<lpage>12465</lpage>. <pub-id pub-id-type="doi">10.1021/jacs.5b08057</pub-id>
</citation>
</ref>
<ref id="B25">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dai</surname>
<given-names>Y. L.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>Y. Q.</given-names>
</name>
<name>
<surname>Hu</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Jiang</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>W. Z.</given-names>
</name>
<name>
<surname>Meng</surname>
<given-names>Y.</given-names>
</name>
<etal/>
</person-group> (<year>2023</year>). <article-title>Nonstructural protein NS17 of grass carp reovirus Honghu strain promotes virus infection by mediating cell-cell fusion and apoptosis</article-title>. <source>Virus Res.</source> <volume>334</volume>, <fpage>199150</fpage>. <pub-id pub-id-type="doi">10.1016/j.virusres.2023.199150</pub-id>
</citation>
</ref>
<ref id="B26">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dominguez-Alvarez</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Racz</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Marc</surname>
<given-names>M. A.</given-names>
</name>
<name>
<surname>Nasim</surname>
<given-names>M. J.</given-names>
</name>
<name>
<surname>Szemeredi</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Viktorova</surname>
<given-names>J.</given-names>
</name>
<etal/>
</person-group> (<year>2022</year>). <article-title>Selenium and tellurium in the development of novel small molecules and nanoparticles as cancer multidrug resistance reversal agents</article-title>. <source>Drug Resist Updat</source> <volume>63</volume>, <fpage>100844</fpage>. <pub-id pub-id-type="doi">10.1016/j.drup.2022.100844</pub-id>
</citation>
</ref>
<ref id="B27">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dubois-Deruy</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Peugnet</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Turkieh</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Pinet</surname>
<given-names>F.</given-names>
</name>
</person-group> (<year>2020</year>). <article-title>Oxidative stress in cardiovascular diseases</article-title>. <source>Antioxidants (Basel)</source> <volume>9</volume>, <fpage>864</fpage>. <pub-id pub-id-type="doi">10.3390/antiox9090864</pub-id>
</citation>
</ref>
<ref id="B28">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dumitrescu</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Biondi</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Xia</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Cardounel</surname>
<given-names>A. J.</given-names>
</name>
<name>
<surname>Druhan</surname>
<given-names>L. J.</given-names>
</name>
<name>
<surname>Ambrosio</surname>
<given-names>G.</given-names>
</name>
<etal/>
</person-group> (<year>2007</year>). <article-title>Myocardial ischemia results in tetrahydrobiopterin (BH4) oxidation with impaired endothelial function ameliorated by BH4</article-title>. <source>Proc. Natl. Acad. Sci. U. S. A.</source> <volume>104</volume>, <fpage>15081</fpage>&#x2013;<lpage>15086</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.0702986104</pub-id>
</citation>
</ref>
<ref id="B29">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gaytan</surname>
<given-names>S. L.</given-names>
</name>
<name>
<surname>Beaven</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Gadad</surname>
<given-names>S. S.</given-names>
</name>
<name>
<surname>Nurunnabi</surname>
<given-names>M.</given-names>
</name>
</person-group> (<year>2023</year>). <article-title>Progress and prospect of nanotechnology for cardiac fibrosis treatment</article-title>. <source>Interdiscip. Med.</source> <volume>1</volume>, <fpage>e20230018</fpage>. <pub-id pub-id-type="doi">10.1002/inmd.20230018</pub-id>
</citation>
</ref>
<ref id="B30">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gong</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Wan</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Yin</surname>
<given-names>J.</given-names>
</name>
</person-group> (<year>2024</year>). <article-title>Management of ROS and regulatory cell death in myocardial ischemia-reperfusion injury</article-title>. <source>Mol. Biotechnol</source>. <pub-id pub-id-type="doi">10.1007/s12033-024-01173-y</pub-id>
</citation>
</ref>
<ref id="B31">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gordan</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Wongjaikam</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Gwathmey</surname>
<given-names>J. K.</given-names>
</name>
<name>
<surname>Chattipakorn</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Chattipakorn</surname>
<given-names>S. C.</given-names>
</name>
<name>
<surname>Xie</surname>
<given-names>L. H.</given-names>
</name>
</person-group> (<year>2018</year>). <article-title>Involvement of cytosolic and mitochondrial iron in iron overload cardiomyopathy: an update</article-title>. <source>Heart Fail. Rev.</source> <volume>23</volume>, <fpage>801</fpage>&#x2013;<lpage>816</lpage>. <pub-id pub-id-type="doi">10.1007/s10741-018-9700-5</pub-id>
</citation>
</ref>
<ref id="B32">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Grimaldi-Bensouda</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Alperovitch</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Aubrun</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Danchin</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Rossignol</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Abenhaim</surname>
<given-names>L.</given-names>
</name>
<etal/>
</person-group> (<year>2015</year>). <article-title>Impact of allopurinol on risk of myocardial infarction</article-title>. <source>Ann. Rheum. Dis.</source> <volume>74</volume>, <fpage>836</fpage>&#x2013;<lpage>842</lpage>. <pub-id pub-id-type="doi">10.1136/annrheumdis-2012-202972</pub-id>
</citation>
</ref>
<ref id="B33">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gruhlke</surname>
<given-names>M. C.</given-names>
</name>
<name>
<surname>Slusarenko</surname>
<given-names>A. J.</given-names>
</name>
</person-group> (<year>2012</year>). <article-title>The biology of reactive sulfur species (RSS)</article-title>. <source>Plant Physiol. Biochem.</source> <volume>59</volume>, <fpage>98</fpage>&#x2013;<lpage>107</lpage>. <pub-id pub-id-type="doi">10.1016/j.plaphy.2012.03.016</pub-id>
</citation>
</ref>
<ref id="B34">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gupta</surname>
<given-names>M. K.</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>S. H.</given-names>
</name>
<name>
<surname>Crowder</surname>
<given-names>S. W.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Hofmeister</surname>
<given-names>L. H.</given-names>
</name>
<name>
<surname>Nelson</surname>
<given-names>C. E.</given-names>
</name>
<etal/>
</person-group> (<year>2015</year>). <article-title>Oligoproline-derived nanocarrier for dual stimuli-responsive gene delivery</article-title>. <source>J. Mater Chem. B</source> <volume>3</volume>, <fpage>7271</fpage>&#x2013;<lpage>7280</lpage>. <pub-id pub-id-type="doi">10.1039/c5tb00988j</pub-id>
</citation>
</ref>
<ref id="B35">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hamidi</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Azadi</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Rafiei</surname>
<given-names>P.</given-names>
</name>
</person-group> (<year>2008</year>). <article-title>Hydrogel nanoparticles in drug delivery</article-title>. <source>Adv. Drug Deliv. Rev.</source> <volume>60</volume>, <fpage>1638</fpage>&#x2013;<lpage>1649</lpage>. <pub-id pub-id-type="doi">10.1016/j.addr.2008.08.002</pub-id>
</citation>
</ref>
<ref id="B36">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Han</surname>
<given-names>G. S.</given-names>
</name>
<name>
<surname>Domaille</surname>
<given-names>D. W.</given-names>
</name>
</person-group> (<year>2022</year>). <article-title>Connecting the dynamics and reactivity of arylboronic acids to emergent and stimuli-responsive material properties</article-title>. <source>J. Mater Chem. B</source> <volume>10</volume>, <fpage>6263</fpage>&#x2013;<lpage>6278</lpage>. <pub-id pub-id-type="doi">10.1039/d2tb00968d</pub-id>
</citation>
</ref>
<ref id="B37">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hao</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Qian</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Midgley</surname>
<given-names>A. C.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>Y.</given-names>
</name>
<etal/>
</person-group> (<year>2022a</year>). <article-title>An injectable dual-function hydrogel protects against myocardial ischemia/reperfusion injury by modulating ROS/NO disequilibrium</article-title>. <source>Adv. Sci. (Weinh)</source> <volume>9</volume>, <fpage>e2105408</fpage>. <pub-id pub-id-type="doi">10.1002/advs.202105408</pub-id>
</citation>
</ref>
<ref id="B38">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hao</surname>
<given-names>Y. M.</given-names>
</name>
<name>
<surname>Song</surname>
<given-names>K. C.</given-names>
</name>
<name>
<surname>Tan</surname>
<given-names>X. C.</given-names>
</name>
<name>
<surname>Ren</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Guo</surname>
<given-names>X. P.</given-names>
</name>
<name>
<surname>Zhou</surname>
<given-names>C. C.</given-names>
</name>
<etal/>
</person-group> (<year>2022b</year>). <article-title>Reactive oxygen species-responsive polypeptide drug delivery system targeted activated hepatic stellate cells to ameliorate liver fibrosis</article-title>. <source>Acs Nano</source> <volume>16</volume>, <fpage>20739</fpage>&#x2013;<lpage>20757</lpage>. <pub-id pub-id-type="doi">10.1021/acsnano.2c07796</pub-id>
</citation>
</ref>
<ref id="B39">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hausenloy</surname>
<given-names>D. J.</given-names>
</name>
<name>
<surname>Yellon</surname>
<given-names>D. M.</given-names>
</name>
</person-group> (<year>2013</year>). <article-title>Myocardial ischemia-reperfusion injury: a neglected therapeutic target</article-title>. <source>J. Clin. Invest.</source> <volume>123</volume>, <fpage>92</fpage>&#x2013;<lpage>100</lpage>. <pub-id pub-id-type="doi">10.1172/jci62874</pub-id>
</citation>
</ref>
<ref id="B40">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Haybar</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Shahrabi</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Rezaeeyan</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Shirzad</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Saki</surname>
<given-names>N.</given-names>
</name>
</person-group> (<year>2019</year>). <article-title>Endothelial cells: from dysfunction mechanism to pharmacological effect in cardiovascular disease</article-title>. <source>Cardiovasc. Toxicol.</source> <volume>19</volume>, <fpage>13</fpage>&#x2013;<lpage>22</lpage>. <pub-id pub-id-type="doi">10.1007/s12012-018-9493-8</pub-id>
</citation>
</ref>
<ref id="B41">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hool</surname>
<given-names>L. C.</given-names>
</name>
</person-group> (<year>2009</year>). <article-title>The L-type Ca(2&#x2b;) channel as a potential mediator of pathology during alterations in cellular redox state</article-title>. <source>Heart Lung Circ.</source> <volume>18</volume>, <fpage>3</fpage>&#x2013;<lpage>10</lpage>. <pub-id pub-id-type="doi">10.1016/j.hlc.2008.11.004</pub-id>
</citation>
</ref>
<ref id="B42">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hou</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Zhao</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Deng</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Yin</surname>
<given-names>L.</given-names>
</name>
</person-group> (<year>2022</year>). <article-title>Endothelial cell-targeting, ROS-ultrasensitive drug/siRNA co-delivery nanocomplexes mitigate early-stage neutrophil recruitment for the anti-inflammatory treatment of myocardial ischemia reperfusion injury</article-title>. <source>Acta Biomater.</source> <volume>143</volume>, <fpage>344</fpage>&#x2013;<lpage>355</lpage>. <pub-id pub-id-type="doi">10.1016/j.actbio.2022.02.018</pub-id>
</citation>
</ref>
<ref id="B43">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Huang</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Zhou</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Ding</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>Y.</given-names>
</name>
<etal/>
</person-group> (<year>2022</year>). <article-title>Biodegradable redox-responsive AIEgen-based-covalent organic framework nanocarriers for long-term treatment of myocardial ischemia/reperfusion injury</article-title>. <source>Small</source> <volume>18</volume>, <fpage>e2205062</fpage>. <pub-id pub-id-type="doi">10.1002/smll.202205062</pub-id>
</citation>
</ref>
<ref id="B44">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ibanez</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Heusch</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Ovize</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Van De Werf</surname>
<given-names>F.</given-names>
</name>
</person-group> (<year>2015</year>). <article-title>Evolving therapies for myocardial ischemia/reperfusion injury</article-title>. <source>J. Am. Coll. Cardiol.</source> <volume>65</volume>, <fpage>1454</fpage>&#x2013;<lpage>1471</lpage>. <pub-id pub-id-type="doi">10.1016/j.jacc.2015.02.032</pub-id>
</citation>
</ref>
<ref id="B45">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ji</surname>
<given-names>X. Q.</given-names>
</name>
<name>
<surname>Meng</surname>
<given-names>Y. B.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>Q. Y.</given-names>
</name>
<name>
<surname>Tong</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Lin</surname>
<given-names>J. Q.</given-names>
</name>
<etal/>
</person-group> (<year>2023</year>). <article-title>Cysteine-based redox-responsive nanoparticles for fibroblast-targeted drug delivery in the treatment of myocardial infarction</article-title>. <source>Acs Nano</source> <volume>17</volume>, <fpage>5421</fpage>&#x2013;<lpage>5434</lpage>. <pub-id pub-id-type="doi">10.1021/acsnano.2c10042</pub-id>
</citation>
</ref>
<ref id="B46">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jordan</surname>
<given-names>J. E.</given-names>
</name>
<name>
<surname>Zhao</surname>
<given-names>Z. Q.</given-names>
</name>
<name>
<surname>Vinten-Johansen</surname>
<given-names>J.</given-names>
</name>
</person-group> (<year>1999</year>). <article-title>The role of neutrophils in myocardial ischemia-reperfusion injury</article-title>. <source>Cardiovasc Res.</source> <volume>43</volume>, <fpage>860</fpage>&#x2013;<lpage>878</lpage>. <pub-id pub-id-type="doi">10.1016/s0008-6363(99)00187-x</pub-id>
</citation>
</ref>
<ref id="B47">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jourden</surname>
<given-names>J. L.</given-names>
</name>
<name>
<surname>Daniel</surname>
<given-names>K. B.</given-names>
</name>
<name>
<surname>Cohen</surname>
<given-names>S. M.</given-names>
</name>
</person-group> (<year>2011</year>). <article-title>Investigation of self-immolative linkers in the design of hydrogen peroxide activated metalloprotein inhibitors</article-title>. <source>Chem. Commun. (Camb)</source> <volume>47</volume>, <fpage>7968</fpage>&#x2013;<lpage>7970</lpage>. <pub-id pub-id-type="doi">10.1039/c1cc12526e</pub-id>
</citation>
</ref>
<ref id="B48">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kahles</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Brandes</surname>
<given-names>R. P.</given-names>
</name>
</person-group> (<year>2013</year>). <article-title>Which NADPH oxidase isoform is relevant for ischemic stroke? The case for nox 2</article-title>. <source>Antioxid. Redox Signal</source> <volume>18</volume>, <fpage>1400</fpage>&#x2013;<lpage>1417</lpage>. <pub-id pub-id-type="doi">10.1089/ars.2012.4721</pub-id>
</citation>
</ref>
<ref id="B49">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kang</surname>
<given-names>I. S.</given-names>
</name>
<name>
<surname>Kwon</surname>
<given-names>K.</given-names>
</name>
</person-group> (<year>2022</year>). <article-title>Potential application of biomimetic exosomes in cardiovascular disease: focused on ischemic heart disease</article-title>. <source>BMB Rep.</source> <volume>55</volume>, <fpage>30</fpage>&#x2013;<lpage>38</lpage>. <pub-id pub-id-type="doi">10.5483/bmbrep.2022.55.1.161</pub-id>
</citation>
</ref>
<ref id="B50">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kang</surname>
<given-names>L. T.</given-names>
</name>
<name>
<surname>Han</surname>
<given-names>X. L.</given-names>
</name>
<name>
<surname>Chang</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Su</surname>
<given-names>Z. P.</given-names>
</name>
<name>
<surname>Fu</surname>
<given-names>F. H.</given-names>
</name>
<name>
<surname>Shan</surname>
<given-names>Y.</given-names>
</name>
<etal/>
</person-group> (<year>2024</year>). <article-title>Redox-sensitive self-assembling polymer micelles based on oleanolic modified hydroxyethyl starch: synthesis, characterisation, and oleanolic release</article-title>. <source>Int. J. Biol. Macromol.</source> <volume>266</volume>, <fpage>131211</fpage>. <pub-id pub-id-type="doi">10.1016/j.ijbiomac.2024.131211</pub-id>
</citation>
</ref>
<ref id="B51">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kieliszek</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Blazejak</surname>
<given-names>S.</given-names>
</name>
</person-group> (<year>2013</year>). <article-title>Selenium: significance, and outlook for supplementation</article-title>. <source>Nutrition</source> <volume>29</volume>, <fpage>713</fpage>&#x2013;<lpage>718</lpage>. <pub-id pub-id-type="doi">10.1016/j.nut.2012.11.012</pub-id>
</citation>
</ref>
<ref id="B52">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Knock</surname>
<given-names>G. A.</given-names>
</name>
</person-group> (<year>2019</year>). <article-title>NADPH oxidase in the vasculature: expression, regulation and signalling pathways; role in normal cardiovascular physiology and its dysregulation in hypertension</article-title>. <source>Free Radic. Biol. Med.</source> <volume>145</volume>, <fpage>385</fpage>&#x2013;<lpage>427</lpage>. <pub-id pub-id-type="doi">10.1016/j.freeradbiomed.2019.09.029</pub-id>
</citation>
</ref>
<ref id="B53">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kobayashi</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Oh</surname>
<given-names>S. H.</given-names>
</name>
<name>
<surname>Yoon</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Gracias</surname>
<given-names>D. H.</given-names>
</name>
</person-group> (<year>2018</year>). <article-title>Multitemperature responsive self-folding soft biomimetic structures</article-title>. <source>Macromol. Rapid Commun.</source> <volume>39</volume>. <pub-id pub-id-type="doi">10.1002/marc.201700692</pub-id>
</citation>
</ref>
<ref id="B54">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Laforgia</surname>
<given-names>P. L.</given-names>
</name>
<name>
<surname>Auguadro</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Bronzato</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Durante</surname>
<given-names>A.</given-names>
</name>
</person-group> (<year>2022</year>). <article-title>The reduction of mortality in acute myocardial infarction: from bed rest to future directions</article-title>. <source>Int. J. Prev. Med.</source> <volume>13</volume>, <fpage>56</fpage>. <pub-id pub-id-type="doi">10.4103/ijpvm.ijpvm_122_20</pub-id>
</citation>
</ref>
<ref id="B55">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Laiva</surname>
<given-names>A. L.</given-names>
</name>
<name>
<surname>Venugopal</surname>
<given-names>J. R.</given-names>
</name>
<name>
<surname>Navaneethan</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Karuppuswamy</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Ramakrishna</surname>
<given-names>S.</given-names>
</name>
</person-group> (<year>2015</year>). <article-title>Biomimetic approaches for cell implantation to the restoration of infarcted myocardium</article-title>. <source>Nanomedicine (Lond)</source> <volume>10</volume>, <fpage>2907</fpage>&#x2013;<lpage>2930</lpage>. <pub-id pub-id-type="doi">10.2217/nnm.15.124</pub-id>
</citation>
</ref>
<ref id="B56">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lan</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Hou</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Yan</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Deng</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Zhao</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Lv</surname>
<given-names>S.</given-names>
</name>
<etal/>
</person-group> (<year>2022</year>). <article-title>Cardiomyocyte-targeted anti-inflammatory nanotherapeutics against myocardial ischemia reperfusion (IR) injury</article-title>. <source>Nano Res.</source> <volume>15</volume>, <fpage>9125</fpage>&#x2013;<lpage>9134</lpage>. <pub-id pub-id-type="doi">10.1007/s12274-022-4553-6</pub-id>
</citation>
</ref>
<ref id="B57">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lee</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Bae</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Hong</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Lim</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Yoon</surname>
<given-names>J. H.</given-names>
</name>
<name>
<surname>Hwang</surname>
<given-names>O.</given-names>
</name>
<etal/>
</person-group> (<year>2013a</year>). <article-title>H2O2-responsive molecularly engineered polymer nanoparticles as ischemia/reperfusion-targeted nanotherapeutic agents</article-title>. <source>Sci. Rep.</source> <volume>3</volume>, <fpage>2233</fpage>. <pub-id pub-id-type="doi">10.1038/srep02233</pub-id>
</citation>
</ref>
<ref id="B58">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lee</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Stubelius</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Hamelmann</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Tran</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Almutairi</surname>
<given-names>A.</given-names>
</name>
</person-group> (<year>2018</year>). <article-title>Inflammation-responsive drug-conjugated dextran nanoparticles enhance anti-inflammatory drug efficacy</article-title>. <source>ACS Appl. Mater Interfaces</source> <volume>10</volume>, <fpage>40378</fpage>&#x2013;<lpage>40387</lpage>. <pub-id pub-id-type="doi">10.1021/acsami.8b08254</pub-id>
</citation>
</ref>
<ref id="B59">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lee</surname>
<given-names>S. H.</given-names>
</name>
<name>
<surname>Boire</surname>
<given-names>T. C.</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>J. B.</given-names>
</name>
<name>
<surname>Gupta</surname>
<given-names>M. K.</given-names>
</name>
<name>
<surname>Zachman</surname>
<given-names>A. L.</given-names>
</name>
<name>
<surname>Rath</surname>
<given-names>R.</given-names>
</name>
<etal/>
</person-group> (<year>2014</year>). <article-title>ROS-cleavable proline oligomer crosslinking of polycaprolactone for pro-angiogenic host response</article-title>. <source>J. Mater Chem. B</source> <volume>2</volume>, <fpage>7109</fpage>&#x2013;<lpage>7113</lpage>. <pub-id pub-id-type="doi">10.1039/c4tb01094a</pub-id>
</citation>
</ref>
<ref id="B60">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lee</surname>
<given-names>S. H.</given-names>
</name>
<name>
<surname>Gupta</surname>
<given-names>M. K.</given-names>
</name>
<name>
<surname>Bang</surname>
<given-names>J. B.</given-names>
</name>
<name>
<surname>Bae</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Sung</surname>
<given-names>H. J.</given-names>
</name>
</person-group> (<year>2013b</year>). <article-title>Current progress in Reactive Oxygen Species (ROS)-Responsive materials for biomedical applications</article-title>. <source>Adv. Healthc. Mater</source> <volume>2</volume>, <fpage>908</fpage>&#x2013;<lpage>915</lpage>. <pub-id pub-id-type="doi">10.1002/adhm.201200423</pub-id>
</citation>
</ref>
<ref id="B61">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Li</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Gao</surname>
<given-names>S.</given-names>
</name>
</person-group> (<year>2023</year>). <article-title>The interplay between T lymphocytes and macrophages in myocardial ischemia/reperfusion injury</article-title>. <source>Mol. Cell Biochem.</source> <volume>479</volume>, <fpage>1925</fpage>&#x2013;<lpage>1936</lpage>. <pub-id pub-id-type="doi">10.1007/s11010-023-04822-z</pub-id>
</citation>
</ref>
<ref id="B62">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Li</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Ji</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Mei</surname>
<given-names>Q.</given-names>
</name>
<etal/>
</person-group> (<year>2022</year>). <article-title>Tregs biomimetic nanoparticle to reprogram inflammatory and redox microenvironment in infarct tissue to treat myocardial ischemia reperfusion injury in mice</article-title>. <source>J. Nanobiotechnology</source> <volume>20</volume>, <fpage>251</fpage>. <pub-id pub-id-type="doi">10.1186/s12951-022-01445-2</pub-id>
</citation>
</ref>
<ref id="B63">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Li</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Guo</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Ni</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Gao</surname>
<given-names>S.</given-names>
</name>
<etal/>
</person-group> (<year>2020</year>). <article-title>Ginsenoside Rg3-loaded, reactive oxygen species-responsive polymeric nanoparticles for alleviating myocardial ischemia-reperfusion injury</article-title>. <source>J. Control Release</source> <volume>317</volume>, <fpage>259</fpage>&#x2013;<lpage>272</lpage>. <pub-id pub-id-type="doi">10.1016/j.jconrel.2019.11.032</pub-id>
</citation>
</ref>
<ref id="B64">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Li</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Ou</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Xie</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>T.</given-names>
</name>
</person-group> (<year>2023</year>). <article-title>Nanomedicine-based therapeutics for myocardial ischemic/reperfusion injury</article-title>. <source>Adv. Healthc. Mater</source>. <volume>12</volume>, <fpage>e2300161</fpage>. <pub-id pub-id-type="doi">10.1002/adhm.202300161</pub-id>
</citation>
</ref>
<ref id="B65">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Li</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Zhu</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Hui</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Bi</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Yu</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>Z.</given-names>
</name>
<etal/>
</person-group> (<year>2021</year>). <article-title>Injection of ROS-responsive hydrogel loaded with basic fibroblast growth factor into the pericardial cavity for heart repair</article-title>. <source>Adv. Funct. Mater.</source> <volume>31</volume>, <fpage>2004377</fpage>. <pub-id pub-id-type="doi">10.1002/adfm.202004377</pub-id>
</citation>
</ref>
<ref id="B66">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Link</surname>
<given-names>W.</given-names>
</name>
</person-group> (<year>2019</year>). <article-title>Introduction to FOXO biology</article-title>. <source>Methods Mol. Biol.</source> <volume>1890</volume>, <fpage>1</fpage>&#x2013;<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1007/978-1-4939-8900-3_1</pub-id>
</citation>
</ref>
<ref id="B67">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Liu</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Thayumanavan</surname>
<given-names>S.</given-names>
</name>
</person-group> (<year>2020</year>). <article-title>Mechanistic investigation on oxidative degradation of ROS-responsive thioacetal/thioketal moieties and their implications</article-title>. <source>Cell Rep. Phys. Sci.</source> <volume>1</volume>, <fpage>100271</fpage>. <pub-id pub-id-type="doi">10.1016/j.xcrp.2020.100271</pub-id>
</citation>
</ref>
<ref id="B68">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Liu</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Zhao</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>Y.</given-names>
</name>
<etal/>
</person-group> (<year>2019</year>). <article-title>Engineering biomimetic platesomes for pH-responsive drug delivery and enhanced antitumor activity</article-title>. <source>Adv. Mater</source>. <volume>31</volume>, <fpage>e1900795</fpage>. <pub-id pub-id-type="doi">10.1002/adma.201900795</pub-id>
</citation>
</ref>
<ref id="B69">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Liu</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>He</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Zhong</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Zhu</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Yan</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Mou</surname>
<given-names>N.</given-names>
</name>
<etal/>
</person-group> (<year>2023a</year>). <article-title>Reactive oxygen species-responsive sequentially targeted AIE fluorescent probe for precisely identifying the atherosclerotic plaques</article-title>. <source>ACS Appl. Mater Interfaces</source> <volume>15</volume>, <fpage>47381</fpage>&#x2013;<lpage>47393</lpage>. <pub-id pub-id-type="doi">10.1021/acsami.3c09573</pub-id>
</citation>
</ref>
<ref id="B70">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Liu</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Zhou</surname>
<given-names>Z.</given-names>
</name>
</person-group> (<year>2023b</year>). <article-title>Myocardial ischemia-reperfusion injury; Molecular mechanisms and prevention</article-title>. <source>Microvasc. Res.</source> <volume>149</volume>, <fpage>104565</fpage>. <pub-id pub-id-type="doi">10.1016/j.mvr.2023.104565</pub-id>
</citation>
</ref>
<ref id="B71">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Liu</surname>
<given-names>Y. H.</given-names>
</name>
<name>
<surname>Carretero</surname>
<given-names>O. A.</given-names>
</name>
<name>
<surname>Cingolani</surname>
<given-names>O. H.</given-names>
</name>
<name>
<surname>Liao</surname>
<given-names>T. D.</given-names>
</name>
<name>
<surname>Sun</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>J.</given-names>
</name>
<etal/>
</person-group> (<year>2005</year>). <article-title>Role of inducible nitric oxide synthase in cardiac function and remodeling in mice with heart failure due to myocardial infarction</article-title>. <source>Am. J. Physiology-Heart Circulatory Physiology</source> <volume>289</volume>, <fpage>H2616</fpage>&#x2013;<lpage>H2623</lpage>. <pub-id pub-id-type="doi">10.1152/ajpheart.00546.2005</pub-id>
</citation>
</ref>
<ref id="B72">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lu</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Mestres</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Singh</surname>
<given-names>V. P.</given-names>
</name>
<name>
<surname>Effati</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Poon</surname>
<given-names>J. F.</given-names>
</name>
<name>
<surname>Engman</surname>
<given-names>L.</given-names>
</name>
<etal/>
</person-group> (<year>2017</year>). <article-title>Selenium- and tellurium-based antioxidants for modulating inflammation and effects on osteoblastic activity</article-title>. <source>Antioxidants (Basel)</source> <volume>6</volume>, <fpage>13</fpage>. <pub-id pub-id-type="doi">10.3390/antiox6010013</pub-id>
</citation>
</ref>
<ref id="B73">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Luo</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Sun</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Sun</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Xiao</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>J.</given-names>
</name>
<etal/>
</person-group> (<year>2023</year>). <article-title>Biomaterials-mediated targeted therapeutics of myocardial ischemia-reperfusion injury</article-title>. <source>Biomaterials</source> <volume>303</volume>, <fpage>122368</fpage>. <pub-id pub-id-type="doi">10.1016/j.biomaterials.2023.122368</pub-id>
</citation>
</ref>
<ref id="B74">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ma</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>X.</given-names>
</name>
</person-group> (<year>2010</year>). <article-title>Dual redox responsive assemblies formed from diselenide block copolymers</article-title>. <source>J. Am. Chem. Soc.</source> <volume>132</volume>, <fpage>442</fpage>&#x2013;<lpage>443</lpage>. <pub-id pub-id-type="doi">10.1021/ja908124g</pub-id>
</citation>
</ref>
<ref id="B75">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Madesh</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Hajnoczky</surname>
<given-names>G.</given-names>
</name>
</person-group> (<year>2001</year>). <article-title>VDAC-dependent permeabilization of the outer mitochondrial membrane by superoxide induces rapid and massive cytochrome c release</article-title>. <source>J. Cell Biol.</source> <volume>155</volume>, <fpage>1003</fpage>&#x2013;<lpage>1015</lpage>. <pub-id pub-id-type="doi">10.1083/jcb.200105057</pub-id>
</citation>
</ref>
<ref id="B76">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Martin</surname>
<given-names>J. R.</given-names>
</name>
<name>
<surname>Gupta</surname>
<given-names>M. K.</given-names>
</name>
<name>
<surname>Page</surname>
<given-names>J. M.</given-names>
</name>
<name>
<surname>Yu</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Davidson</surname>
<given-names>J. M.</given-names>
</name>
<name>
<surname>Guelcher</surname>
<given-names>S. A.</given-names>
</name>
<etal/>
</person-group> (<year>2014</year>). <article-title>A porous tissue engineering scaffold selectively degraded by cell-generated reactive oxygen species</article-title>. <source>Biomaterials</source> <volume>35</volume>, <fpage>3766</fpage>&#x2013;<lpage>3776</lpage>. <pub-id pub-id-type="doi">10.1016/j.biomaterials.2014.01.026</pub-id>
</citation>
</ref>
<ref id="B77">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mount</surname>
<given-names>P. F.</given-names>
</name>
<name>
<surname>Kemp</surname>
<given-names>B. E.</given-names>
</name>
<name>
<surname>Power</surname>
<given-names>D. A.</given-names>
</name>
</person-group> (<year>2007</year>). <article-title>Regulation of endothelial and myocardial NO synthesis by multi-site eNOS phosphorylation</article-title>. <source>J. Mol. Cell Cardiol.</source> <volume>42</volume>, <fpage>271</fpage>&#x2013;<lpage>279</lpage>. <pub-id pub-id-type="doi">10.1016/j.yjmcc.2006.05.023</pub-id>
</citation>
</ref>
<ref id="B78">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Paradies</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Petrosillo</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Pistolese</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Di Venosa</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Federici</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Ruggiero</surname>
<given-names>F. M.</given-names>
</name>
</person-group> (<year>2004</year>). <article-title>Decrease in mitochondrial complex I activity in ischemic/reperfused rat heart: involvement of reactive oxygen species and cardiolipin</article-title>. <source>Circ. Res.</source> <volume>94</volume>, <fpage>53</fpage>&#x2013;<lpage>59</lpage>. <pub-id pub-id-type="doi">10.1161/01.res.0000109416.56608.64</pub-id>
</citation>
</ref>
<ref id="B79">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Paravicini</surname>
<given-names>T. M.</given-names>
</name>
<name>
<surname>Touyz</surname>
<given-names>R. M.</given-names>
</name>
</person-group> (<year>2008</year>). <article-title>NADPH oxidases, reactive oxygen species, and hypertension: clinical implications and therapeutic possibilities</article-title>. <source>Diabetes Care</source> <volume>31</volume> (<issue>Suppl. 2</issue>), <fpage>S170</fpage>&#x2013;<lpage>S180</lpage>. <pub-id pub-id-type="doi">10.2337/dc08-s247</pub-id>
</citation>
</ref>
<ref id="B80">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Qiu</surname>
<given-names>Y. W.</given-names>
</name>
<name>
<surname>Yu</surname>
<given-names>C. J.</given-names>
</name>
<name>
<surname>Yue</surname>
<given-names>Z. W.</given-names>
</name>
<name>
<surname>Ren</surname>
<given-names>Y. C.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>W. T.</given-names>
</name>
<name>
<surname>Yu</surname>
<given-names>Q. Y.</given-names>
</name>
<etal/>
</person-group> (<year>2024</year>). <article-title>Chronological-programmed black phosphorus hydrogel for responsive modulation of the pathological microenvironment in myocardial infarction</article-title>. <source>Acs Appl. Mater. and Interfaces</source> <volume>16</volume>, <fpage>17323</fpage>&#x2013;<lpage>17338</lpage>. <pub-id pub-id-type="doi">10.1021/acsami.4c01956</pub-id>
</citation>
</ref>
<ref id="B81">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Radi</surname>
<given-names>R.</given-names>
</name>
</person-group> (<year>2013</year>). <article-title>Peroxynitrite, a stealthy biological oxidant</article-title>. <source>J. Biol. Chem.</source> <volume>288</volume>, <fpage>26464</fpage>&#x2013;<lpage>26472</lpage>. <pub-id pub-id-type="doi">10.1074/jbc.r113.472936</pub-id>
</citation>
</ref>
<ref id="B82">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Reed</surname>
<given-names>G. W.</given-names>
</name>
<name>
<surname>Rossi</surname>
<given-names>J. E.</given-names>
</name>
<name>
<surname>Cannon</surname>
<given-names>C. P.</given-names>
</name>
</person-group> (<year>2017</year>). <article-title>Acute myocardial infarction</article-title>. <source>Lancet</source> <volume>389</volume>, <fpage>197</fpage>&#x2013;<lpage>210</lpage>. <pub-id pub-id-type="doi">10.1016/s0140-6736(16)30677-8</pub-id>
</citation>
</ref>
<ref id="B83">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rios</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Longo</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Zahouani</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Garnier</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Vogt</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Reisch</surname>
<given-names>A.</given-names>
</name>
<etal/>
</person-group> (<year>2015</year>). <article-title>A new biomimetic route to engineer enzymatically active mechano-responsive materials</article-title>. <source>Chem. Commun. (Camb)</source> <volume>51</volume>, <fpage>5622</fpage>&#x2013;<lpage>5625</lpage>. <pub-id pub-id-type="doi">10.1039/c5cc00329f</pub-id>
</citation>
</ref>
<ref id="B84">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Romanyuk</surname>
<given-names>A. V.</given-names>
</name>
<name>
<surname>Grozdova</surname>
<given-names>I. D.</given-names>
</name>
<name>
<surname>Ezhov</surname>
<given-names>A. A.</given-names>
</name>
<name>
<surname>Melik-Nubarov</surname>
<given-names>N. S.</given-names>
</name>
</person-group> (<year>2017</year>). <article-title>Peroxyoxalate chemiluminescent reaction as a tool for elimination of tumour cells under oxidative stress</article-title>. <source>Sci. Rep.</source> <volume>7</volume>, <fpage>3410</fpage>. <pub-id pub-id-type="doi">10.1038/s41598-017-03527-w</pub-id>
</citation>
</ref>
<ref id="B85">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sah</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Thoma</surname>
<given-names>L. A.</given-names>
</name>
<name>
<surname>Desu</surname>
<given-names>H. R.</given-names>
</name>
<name>
<surname>Sah</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Wood</surname>
<given-names>G. C.</given-names>
</name>
</person-group> (<year>2013</year>). <article-title>Concepts and practices used to develop functional PLGA-based nanoparticulate systems</article-title>. <source>Int. J. Nanomedicine</source> <volume>8</volume>, <fpage>747</fpage>&#x2013;<lpage>765</lpage>. <pub-id pub-id-type="doi">10.2147/ijn.s40579</pub-id>
</citation>
</ref>
<ref id="B86">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Saito</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Oyama</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Tsujita</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Yasuda</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Kobayashi</surname>
<given-names>Y.</given-names>
</name>
</person-group> (<year>2023</year>). <article-title>Treatment strategies of acute myocardial infarction: updates on revascularization, pharmacological therapy, and beyond</article-title>. <source>J. Cardiol.</source> <volume>81</volume>, <fpage>168</fpage>&#x2013;<lpage>178</lpage>. <pub-id pub-id-type="doi">10.1016/j.jjcc.2022.07.003</pub-id>
</citation>
</ref>
<ref id="B87">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Schanze</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Hamad</surname>
<given-names>M. A.</given-names>
</name>
<name>
<surname>Nuhrenberg</surname>
<given-names>T. G.</given-names>
</name>
<name>
<surname>Bode</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Duerschmied</surname>
<given-names>D.</given-names>
</name>
</person-group> (<year>2023</year>). <article-title>Platelets in myocardial ischemia/reperfusion injury</article-title>. <source>Hamostaseologie</source> <volume>43</volume>, <fpage>110</fpage>&#x2013;<lpage>121</lpage>. <pub-id pub-id-type="doi">10.1055/a-1739-9351</pub-id>
</citation>
</ref>
<ref id="B88">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shen</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Gao</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Zhan</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Lan</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>Z.</given-names>
</name>
<etal/>
</person-group> (<year>2021</year>). <article-title>Reactive oxygen species (ROS)-responsive nanoprobe for bioimaging and targeting therapy of osteoarthritis</article-title>. <source>J. Nanobiotechnology</source> <volume>19</volume>, <fpage>395</fpage>. <pub-id pub-id-type="doi">10.1186/s12951-021-01136-4</pub-id>
</citation>
</ref>
<ref id="B89">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shen</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Jiao</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Yuan</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Xie</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Wei</surname>
<given-names>M.</given-names>
</name>
<etal/>
</person-group> (<year>2024</year>). <article-title>Oral curcumin-thioketal-inulin conjugate micelles against radiation-induced enteritis</article-title>. <source>Antioxidants (Basel)</source> <volume>13</volume>, <fpage>417</fpage>. <pub-id pub-id-type="doi">10.3390/antiox13040417</pub-id>
</citation>
</ref>
<ref id="B90">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shofolawe-Bakare</surname>
<given-names>O. T.</given-names>
</name>
<name>
<surname>De Mel</surname>
<given-names>J. U.</given-names>
</name>
<name>
<surname>Mishra</surname>
<given-names>S. K.</given-names>
</name>
<name>
<surname>Hossain</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Hamadani</surname>
<given-names>C. M.</given-names>
</name>
<name>
<surname>Pride</surname>
<given-names>M. C.</given-names>
</name>
<etal/>
</person-group> (<year>2022</year>). <article-title>ROS-responsive glycopolymeric nanoparticles for enhanced drug delivery to macrophages</article-title>. <source>Macromol. Biosci.</source> <volume>22</volume>, <fpage>e2200281</fpage>. <pub-id pub-id-type="doi">10.1002/mabi.202200281</pub-id>
</citation>
</ref>
<ref id="B91">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sies</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Belousov</surname>
<given-names>V. V.</given-names>
</name>
<name>
<surname>Chandel</surname>
<given-names>N. S.</given-names>
</name>
<name>
<surname>Davies</surname>
<given-names>M. J.</given-names>
</name>
<name>
<surname>Jones</surname>
<given-names>D. P.</given-names>
</name>
<name>
<surname>Mann</surname>
<given-names>G. E.</given-names>
</name>
<etal/>
</person-group> (<year>2022</year>). <article-title>Defining roles of specific reactive oxygen species (ROS) in cell biology and physiology</article-title>. <source>Nat. Rev. Mol. Cell Biol.</source> <volume>23</volume>, <fpage>499</fpage>&#x2013;<lpage>515</lpage>. <pub-id pub-id-type="doi">10.1038/s41580-022-00456-z</pub-id>
</citation>
</ref>
<ref id="B92">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Stubelius</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Almutairi</surname>
<given-names>A.</given-names>
</name>
</person-group> (<year>2019</year>). <article-title>The chemistry of boronic acids in nanomaterials for drug delivery</article-title>. <source>Acc. Chem. Res.</source> <volume>52</volume>, <fpage>3108</fpage>&#x2013;<lpage>3119</lpage>. <pub-id pub-id-type="doi">10.1021/acs.accounts.9b00292</pub-id>
</citation>
</ref>
<ref id="B93">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sun</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Xue</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Bai</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Tian</surname>
<given-names>Y.</given-names>
</name>
<etal/>
</person-group> (<year>2023</year>). <article-title>ROS-responsive ADPH nanoparticles for image-guided surgery</article-title>. <source>Front. Chem.</source> <volume>11</volume>, <fpage>1121957</fpage>. <pub-id pub-id-type="doi">10.3389/fchem.2023.1121957</pub-id>
</citation>
</ref>
<ref id="B94">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sun</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>S. Y.</given-names>
</name>
<name>
<surname>Flower</surname>
<given-names>S. E.</given-names>
</name>
<name>
<surname>Fossey</surname>
<given-names>J. S.</given-names>
</name>
<name>
<surname>Qian</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>James</surname>
<given-names>T. D.</given-names>
</name>
</person-group> (<year>2013</year>). <article-title>&#x201c;Integrated&#x201d; and &#x201c;insulated&#x201d; boronate-based fluorescent probes for the detection of hydrogen peroxide</article-title>. <source>Chem. Commun. (Camb)</source> <volume>49</volume>, <fpage>8311</fpage>&#x2013;<lpage>8313</lpage>. <pub-id pub-id-type="doi">10.1039/c3cc43265c</pub-id>
</citation>
</ref>
<ref id="B95">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sun</surname>
<given-names>Y. G.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>X. P.</given-names>
</name>
<name>
<surname>Nie</surname>
<given-names>X. F.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Zhao</surname>
<given-names>X. R.</given-names>
</name>
<name>
<surname>Cui</surname>
<given-names>C. Y.</given-names>
</name>
<etal/>
</person-group> (<year>2024</year>). <article-title>Dough-kneading-inspired design of an adhesive cardiac patch to attenuate cardiac fibrosis and improve cardiac function via regulating glycometabolism</article-title>. <source>Adv. Healthc. Mater.</source> <volume>13</volume>, <fpage>e2303685</fpage>. <pub-id pub-id-type="doi">10.1002/adhm.202303685</pub-id>
</citation>
</ref>
<ref id="B96">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Surendran</surname>
<given-names>S. P.</given-names>
</name>
<name>
<surname>Thomas</surname>
<given-names>R. G.</given-names>
</name>
<name>
<surname>Moon</surname>
<given-names>M. J.</given-names>
</name>
<name>
<surname>Park</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>J. H.</given-names>
</name>
<name>
<surname>Jeong</surname>
<given-names>Y. Y.</given-names>
</name>
</person-group> (<year>2020</year>). <article-title>A bilirubin-conjugated chitosan nanotheranostics system as a platform for reactive oxygen species stimuli-responsive hepatic fibrosis therapy</article-title>. <source>Acta Biomater.</source> <volume>116</volume>, <fpage>356</fpage>&#x2013;<lpage>367</lpage>. <pub-id pub-id-type="doi">10.1016/j.actbio.2020.09.014</pub-id>
</citation>
</ref>
<ref id="B97">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Takaya</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Katoh</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Iwabuchi</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Hayashi</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Konishi</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Itoh</surname>
<given-names>S.</given-names>
</name>
<etal/>
</person-group> (<year>2005</year>). <article-title>Platelets activated by collagen through the immunoreceptor tyrosine-based activation motif in the Fc receptor gamma-chain play a pivotal role in the development of myocardial ischemia-reperfusion injury</article-title>. <source>J. Mol. Cell Cardiol.</source> <volume>39</volume>, <fpage>856</fpage>&#x2013;<lpage>864</lpage>. <pub-id pub-id-type="doi">10.1016/j.yjmcc.2005.07.006</pub-id>
</citation>
</ref>
<ref id="B98">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tan</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Yu</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>Z.</given-names>
</name>
<etal/>
</person-group> (<year>2012</year>). <article-title>Single-molecule force spectroscopy of selenium-containing amphiphilic block copolymer: toward disassembling the polymer micelles</article-title>. <source>Langmuir</source> <volume>28</volume>, <fpage>9601</fpage>&#x2013;<lpage>9605</lpage>. <pub-id pub-id-type="doi">10.1021/la301703t</pub-id>
</citation>
</ref>
<ref id="B99">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Thirunavukkarasu</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Adluri</surname>
<given-names>R. S.</given-names>
</name>
<name>
<surname>Juhasz</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Samuel</surname>
<given-names>S. M.</given-names>
</name>
<name>
<surname>Zhan</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Kaur</surname>
<given-names>A.</given-names>
</name>
<etal/>
</person-group> (<year>2012</year>). <article-title>Novel role of NADPH oxidase in ischemic myocardium: a study with Nox2 knockout mice</article-title>. <source>Funct. Integr. Genomics</source> <volume>12</volume>, <fpage>501</fpage>&#x2013;<lpage>514</lpage>. <pub-id pub-id-type="doi">10.1007/s10142-011-0256-x</pub-id>
</citation>
</ref>
<ref id="B100">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Thygesen</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Alpert</surname>
<given-names>J. S.</given-names>
</name>
<name>
<surname>White</surname>
<given-names>H. D.</given-names>
</name>
<name>
<surname>Jaffe</surname>
<given-names>A. S.</given-names>
</name>
<name>
<surname>Apple</surname>
<given-names>F. S.</given-names>
</name>
<name>
<surname>Galvani</surname>
<given-names>M.</given-names>
</name>
<etal/>
</person-group> (<year>2007</year>). <article-title>Universal definition of myocardial infarction</article-title>. <source>Circulation</source> <volume>116</volume>, <fpage>2634</fpage>&#x2013;<lpage>2653</lpage>. <pub-id pub-id-type="doi">10.1161/circulationaha.107.187397</pub-id>
</citation>
</ref>
<ref id="B101">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tian</surname>
<given-names>Z. Y.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Lu</surname>
<given-names>H.</given-names>
</name>
</person-group> (<year>2021</year>). <article-title>Hydroxyproline-derived biomimetic and biodegradable polymers</article-title>. <source>Curr. Opin. Solid State and Mater. Sci.</source> <volume>25</volume>, <fpage>100902</fpage>. <pub-id pub-id-type="doi">10.1016/j.cossms.2021.100902</pub-id>
</citation>
</ref>
<ref id="B102">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Vinogradov</surname>
<given-names>A. D.</given-names>
</name>
<name>
<surname>Grivennikova</surname>
<given-names>V. G.</given-names>
</name>
</person-group> (<year>2016</year>). <article-title>Oxidation of NADH and ROS production by respiratory complex I</article-title>. <source>Biochim. Biophys. Acta</source> <volume>1857</volume>, <fpage>863</fpage>&#x2013;<lpage>871</lpage>. <pub-id pub-id-type="doi">10.1016/j.bbabio.2015.11.004</pub-id>
</citation>
</ref>
<ref id="B103">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Xia</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Jia</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>G.</given-names>
</name>
<etal/>
</person-group> (<year>2020</year>). <article-title>Preparation of ROS-responsive core crosslinked polycarbonate micelles with thioketal linkage</article-title>. <source>Colloids Surf. B Biointerfaces</source> <volume>195</volume>, <fpage>111276</fpage>. <pub-id pub-id-type="doi">10.1016/j.colsurfb.2020.111276</pub-id>
</citation>
</ref>
<ref id="B104">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Zhou</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>W.</given-names>
</name>
<etal/>
</person-group> (<year>2022</year>). <article-title>ROS-responsive thioether-containing hyperbranched polymer micelles for light-triggered drug release</article-title>. <source>SmartMat</source> <volume>3</volume>, <fpage>522</fpage>&#x2013;<lpage>531</lpage>. <pub-id pub-id-type="doi">10.1002/smm2.1092</pub-id>
</citation>
</ref>
<ref id="B105">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Fan</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Cao</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>H.</given-names>
</name>
</person-group> (<year>2015</year>). <article-title>Ultrasensitive ROS-responsive coassemblies of tellurium-containing molecules and phospholipids</article-title>. <source>ACS Appl. Mater Interfaces</source> <volume>7</volume>, <fpage>16054</fpage>&#x2013;<lpage>16060</lpage>. <pub-id pub-id-type="doi">10.1021/acsami.5b04419</pub-id>
</citation>
</ref>
<ref id="B106">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Weng</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Tan</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>Q.</given-names>
</name>
<etal/>
</person-group> (<year>2022</year>). <article-title>Targeted delivery and ROS-responsive release of Resolvin D1 by platelet chimeric liposome ameliorates myocardial ischemia-reperfusion injury</article-title>. <source>J. Nanobiotechnology</source> <volume>20</volume>, <fpage>454</fpage>. <pub-id pub-id-type="doi">10.1186/s12951-022-01652-x</pub-id>
</citation>
</ref>
<ref id="B107">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wu</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Cao</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Zhao</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Zeng</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Tu</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Zhao</surname>
<given-names>J.</given-names>
</name>
</person-group> (<year>2016</year>). <article-title>Novel self-assembled pH-responsive biomimetic nanocarriers for drug delivery</article-title>. <source>Mater Sci. Eng. C Mater Biol. Appl.</source> <volume>64</volume>, <fpage>346</fpage>&#x2013;<lpage>353</lpage>. <pub-id pub-id-type="doi">10.1016/j.msec.2016.03.099</pub-id>
</citation>
</ref>
<ref id="B108">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Xia</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Ke</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Han</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Ma</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Shi</surname>
<given-names>Q.</given-names>
</name>
</person-group> (<year>2023</year>). <article-title>ROS-responsive phenylboronic ester-based nanovesicles as multifunctional drug delivery systems for the treatment of inflammatory and thrombotic complications</article-title>. <source>Biomater. Sci.</source> <volume>11</volume>, <fpage>7805</fpage>&#x2013;<lpage>7816</lpage>. <pub-id pub-id-type="doi">10.1039/d3bm01427d</pub-id>
</citation>
</ref>
<ref id="B109">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Xie</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Yao</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Fan</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Ding</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Gao</surname>
<given-names>Y.</given-names>
</name>
<etal/>
</person-group> (<year>2022</year>). <article-title>Alleviating oxidative injury of myocardial infarction by a fibrous polyurethane patch with condensed ROS-scavenging backbone units</article-title>. <source>Adv. Healthc. Mater</source> <volume>11</volume>, <fpage>e2101855</fpage>. <pub-id pub-id-type="doi">10.1002/adhm.202101855</pub-id>
</citation>
</ref>
<ref id="B110">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Xu</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Cao</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>X.</given-names>
</name>
</person-group> (<year>2013</year>). <article-title>Selenium-containing polymers: promising biomaterials for controlled release and enzyme mimics</article-title>. <source>Acc. Chem. Res.</source> <volume>46</volume>, <fpage>1647</fpage>&#x2013;<lpage>1658</lpage>. <pub-id pub-id-type="doi">10.1021/ar4000339</pub-id>
</citation>
</ref>
<ref id="B111">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Xu</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>He</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Ren</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Xiao</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>X.</given-names>
</name>
</person-group> (<year>2016a</year>). <article-title>Thermosensitive polypeptide hydrogels as a platform for ROS-triggered cargo release with innate cytoprotective ability under oxidative stress</article-title>. <source>Adv. Healthc. Mater</source> <volume>5</volume>, <fpage>1979</fpage>&#x2013;<lpage>1990</lpage>. <pub-id pub-id-type="doi">10.1002/adhm.201600292</pub-id>
</citation>
</ref>
<ref id="B112">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Xu</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>He</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Xiao</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>X.</given-names>
</name>
</person-group> (<year>2016b</year>). <article-title>Reactive oxygen species (ROS) responsive polymers for biomedical applications</article-title>. <source>Macromol. Biosci.</source> <volume>16</volume>, <fpage>635</fpage>&#x2013;<lpage>646</lpage>. <pub-id pub-id-type="doi">10.1002/mabi.201500440</pub-id>
</citation>
</ref>
<ref id="B113">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Xu</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>J.</given-names>
</name>
</person-group> (<year>2022</year>). <article-title>Reactive oxygen species-responsive and self-illuminating nanoparticles for inflammation and tumor imaging</article-title>. <source>Methods Mol. Biol.</source> <volume>2525</volume>, <fpage>21</fpage>&#x2013;<lpage>34</lpage>. <pub-id pub-id-type="doi">10.1007/978-1-0716-2473-9_3</pub-id>
</citation>
</ref>
<ref id="B114">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Xu</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Huo</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Toufektsian</surname>
<given-names>M. C.</given-names>
</name>
<name>
<surname>Ramos</surname>
<given-names>S. I.</given-names>
</name>
<name>
<surname>Ma</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Tejani</surname>
<given-names>A. D.</given-names>
</name>
<etal/>
</person-group> (<year>2006</year>). <article-title>Activated platelets contribute importantly to myocardial reperfusion injury</article-title>. <source>Am. J. Physiol. Heart Circ. Physiol.</source> <volume>290</volume>, <fpage>H692</fpage>&#x2013;<lpage>H699</lpage>. <pub-id pub-id-type="doi">10.1152/ajpheart.00634.2005</pub-id>
</citation>
</ref>
<ref id="B115">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yaman</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Chintapula</surname>
<given-names>U.</given-names>
</name>
<name>
<surname>Rodriguez</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Ramachandramoorthy</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Nguyen</surname>
<given-names>K. T.</given-names>
</name>
</person-group> (<year>2020</year>). <article-title>Cell-mediated and cell membrane-coated nanoparticles for drug delivery and cancer therapy</article-title>. <source>Cancer Drug Resist</source> <volume>3</volume>, <fpage>879</fpage>&#x2013;<lpage>911</lpage>. <pub-id pub-id-type="doi">10.20517/cdr.2020.55</pub-id>
</citation>
</ref>
<ref id="B116">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yang</surname>
<given-names>J. W.</given-names>
</name>
<name>
<surname>Dong</surname>
<given-names>X. Z.</given-names>
</name>
<name>
<surname>Wei</surname>
<given-names>W. Y.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>X. P.</given-names>
</name>
<name>
<surname>Dai</surname>
<given-names>H. L.</given-names>
</name>
</person-group> (<year>2024</year>). <article-title>An injectable hydrogel dressing for controlled release of hydrogen sulfide pleiotropically mediates the wound microenvironment</article-title>. <source>J. Mater. Chem. B</source> <volume>12</volume>, <fpage>5377</fpage>&#x2013;<lpage>5390</lpage>. <pub-id pub-id-type="doi">10.1039/d4tb00411f</pub-id>
</citation>
</ref>
<ref id="B117">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yang</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>He</surname>
<given-names>G. W.</given-names>
</name>
<name>
<surname>Underwood</surname>
<given-names>M. J.</given-names>
</name>
<name>
<surname>Yu</surname>
<given-names>C. M.</given-names>
</name>
</person-group> (<year>2016</year>). <article-title>Cellular and molecular mechanisms of endothelial ischemia/reperfusion injury: perspectives and implications for postischemic myocardial protection</article-title>. <source>Am. J. Transl. Res.</source> <volume>8</volume>, <fpage>765</fpage>&#x2013;<lpage>777</lpage>.</citation>
</ref>
<ref id="B118">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yao</surname>
<given-names>M. Y.</given-names>
</name>
<name>
<surname>Lu</surname>
<given-names>Y. F.</given-names>
</name>
<name>
<surname>Shi</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Tan</surname>
<given-names>J. L.</given-names>
</name>
<etal/>
</person-group> (<year>2022a</year>). <article-title>A ROS-responsive, self-immolative and self-reporting hydrogen sulfide donor with multiple biological activities for the treatment of myocardial infarction</article-title>. <source>Bioact. Mater.</source> <volume>9</volume>, <fpage>168</fpage>&#x2013;<lpage>182</lpage>. <pub-id pub-id-type="doi">10.1016/j.bioactmat.2021.07.011</pub-id>
</citation>
</ref>
<ref id="B119">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yao</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Lu</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Xie</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>H.</given-names>
</name>
<etal/>
</person-group> (<year>2022b</year>). <article-title>Multifunctional elastomer cardiac patches for preventing left ventricle remodeling after myocardial infarction <italic>in vivo</italic>
</article-title>. <source>Biomaterials</source> <volume>282</volume>, <fpage>121382</fpage>. <pub-id pub-id-type="doi">10.1016/j.biomaterials.2022.121382</pub-id>
</citation>
</ref>
<ref id="B120">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yellon</surname>
<given-names>D. M.</given-names>
</name>
<name>
<surname>Hausenloy</surname>
<given-names>D. J.</given-names>
</name>
</person-group> (<year>2007</year>). <article-title>Myocardial reperfusion injury</article-title>. <source>N. Engl. J. Med.</source> <volume>357</volume>, <fpage>1121</fpage>&#x2013;<lpage>1135</lpage>. <pub-id pub-id-type="doi">10.1056/nejmra071667</pub-id>
</citation>
</ref>
<ref id="B121">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yoo</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Rejinold</surname>
<given-names>N. S.</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Jon</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>Y. C.</given-names>
</name>
</person-group> (<year>2017</year>). <article-title>Protease-activatable cell-penetrating peptide possessing ROS-triggered phase transition for enhanced cancer therapy</article-title>. <source>J. Control. Release</source> <volume>264</volume>, <fpage>89</fpage>&#x2013;<lpage>101</lpage>. <pub-id pub-id-type="doi">10.1016/j.jconrel.2017.08.026</pub-id>
</citation>
</ref>
<ref id="B122">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yu</surname>
<given-names>S. S.</given-names>
</name>
<name>
<surname>Koblin</surname>
<given-names>R. L.</given-names>
</name>
<name>
<surname>Zachman</surname>
<given-names>A. L.</given-names>
</name>
<name>
<surname>Perrien</surname>
<given-names>D. S.</given-names>
</name>
<name>
<surname>Hofmeister</surname>
<given-names>L. H.</given-names>
</name>
<name>
<surname>Giorgio</surname>
<given-names>T. D.</given-names>
</name>
<etal/>
</person-group> (<year>2011</year>). <article-title>Physiologically relevant oxidative degradation of oligo(proline) cross-linked polymeric scaffolds</article-title>. <source>Biomacromolecules</source> <volume>12</volume>, <fpage>4357</fpage>&#x2013;<lpage>4366</lpage>. <pub-id pub-id-type="doi">10.1021/bm201328k</pub-id>
</citation>
</ref>
<ref id="B123">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yu</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Deng</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Kou</surname>
<given-names>M. T.</given-names>
</name>
<etal/>
</person-group> (<year>2024</year>). <article-title>Biomimetic nanomaterials in myocardial infarction treatment: harnessing bionic strategies for advanced therapeutics</article-title>. <source>Mater Today Bio</source> <volume>25</volume>, <fpage>100957</fpage>. <pub-id pub-id-type="doi">10.1016/j.mtbio.2024.100957</pub-id>
</citation>
</ref>
<ref id="B124">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yu</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Ge</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Niu</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Lian</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Ma</surname>
<given-names>H. C.</given-names>
</name>
<name>
<surname>Pang</surname>
<given-names>L.</given-names>
</name>
</person-group> (<year>2018</year>). <article-title>The dual role of inducible nitric oxide synthase in myocardial ischemia/reperfusion injury: friend or foe?</article-title> <source>Oxidative Med. Cell. Longev.</source> <volume>2018</volume>, <fpage>8364848</fpage>. <pub-id pub-id-type="doi">10.1155/2018/8364848</pub-id>
</citation>
</ref>
<ref id="B125">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yuan</surname>
<given-names>X. Y.</given-names>
</name>
<name>
<surname>Jia</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>Y. N.</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>Y. Q.</given-names>
</name>
<name>
<surname>Gong</surname>
<given-names>Y. C.</given-names>
</name>
<etal/>
</person-group> (<year>2021</year>). <article-title>A diselenide bond-containing ROS-responsive ruthenium nanoplatform delivers nerve growth factor for Alzheimer&#x27;s disease management by repairing and promoting neuron regeneration</article-title>. <source>J. Mater. Chem. B</source> <volume>9</volume>, <fpage>7835</fpage>&#x2013;<lpage>7847</lpage>. <pub-id pub-id-type="doi">10.1039/d1tb01290h</pub-id>
</citation>
</ref>
<ref id="B126">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yue</surname>
<given-names>T. J.</given-names>
</name>
<name>
<surname>Ren</surname>
<given-names>W. M.</given-names>
</name>
<name>
<surname>Lu</surname>
<given-names>X. B.</given-names>
</name>
</person-group> (<year>2023</year>). <article-title>Copolymerization involving sulfur-containing monomers</article-title>. <source>Chem. Rev.</source> <volume>123</volume>, <fpage>14038</fpage>&#x2013;<lpage>14083</lpage>. <pub-id pub-id-type="doi">10.1021/acs.chemrev.3c00437</pub-id>
</citation>
</ref>
<ref id="B127">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhang</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Wei</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Shi</surname>
<given-names>Q.</given-names>
</name>
<etal/>
</person-group> (<year>2015</year>). <article-title>Biocompatible reactive oxygen species (ROS)-responsive nanoparticles as superior drug delivery vehicles</article-title>. <source>Adv. Healthc. Mater</source> <volume>4</volume>, <fpage>69</fpage>&#x2013;<lpage>76</lpage>. <pub-id pub-id-type="doi">10.1002/adhm.201400299</pub-id>
</citation>
</ref>
<ref id="B128">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhang</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Su</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Tang</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>Z.</given-names>
</name>
<etal/>
</person-group> (<year>2024a</year>). <article-title>A responsive hydrogel modulates innate immune cascade fibrosis to promote ocular surface reconstruction after chemical injury</article-title>. <source>J. Control Release</source> <volume>365</volume>, <fpage>1124</fpage>&#x2013;<lpage>1138</lpage>. <pub-id pub-id-type="doi">10.1016/j.jconrel.2023.12.025</pub-id>
</citation>
</ref>
<ref id="B129">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhang</surname>
<given-names>J. H.</given-names>
</name>
<name>
<surname>Sun</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Guo</surname>
<given-names>Y. S.</given-names>
</name>
<name>
<surname>Tong</surname>
<given-names>J. R.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>Q. Y.</given-names>
</name>
<name>
<surname>Gao</surname>
<given-names>R.</given-names>
</name>
<etal/>
</person-group> (<year>2024b</year>). <article-title>Targeted delivery of black phosphorus nanosheets by ROS responsive complex hydrogel based on angiogenesis and antioxidant promotes myocardial infarction repair</article-title>. <source>J. Nanobiotechnology</source> <volume>22</volume>, <fpage>433</fpage>. <pub-id pub-id-type="doi">10.1186/s12951-024-02685-0</pub-id>
</citation>
</ref>
<ref id="B130">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhang</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Sun</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>J.</given-names>
</name>
<etal/>
</person-group> (<year>2022a</year>). <article-title>An injectable mitochondria-targeted nanodrug loaded-hydrogel for restoring mitochondrial function and hierarchically attenuating oxidative stress to reduce myocardial ischemia-reperfusion injury</article-title>. <source>Biomaterials</source> <volume>287</volume>, <fpage>121656</fpage>. <pub-id pub-id-type="doi">10.1016/j.biomaterials.2022.121656</pub-id>
</citation>
</ref>
<ref id="B131">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhang</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Dalan</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Hu</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>J. W.</given-names>
</name>
<name>
<surname>Chew</surname>
<given-names>N. W.</given-names>
</name>
<name>
<surname>Poh</surname>
<given-names>K. K.</given-names>
</name>
<etal/>
</person-group> (<year>2022b</year>). <article-title>Reactive oxygen species scavenging nanomedicine for the treatment of ischemic heart disease</article-title>. <source>Adv. Mater</source> <volume>34</volume>, <fpage>e2202169</fpage>. <pub-id pub-id-type="doi">10.1002/adma.202202169</pub-id>
</citation>
</ref>
<ref id="B132">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zheng</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Lei</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Jiang</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Zhou</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Zhao</surname>
<given-names>Y.</given-names>
</name>
<etal/>
</person-group> (<year>2022a</year>). <article-title>A ROS-responsive liposomal composite hydrogel integrating improved mitochondrial function and pro-angiogenesis for efficient treatment of myocardial infarction</article-title>. <source>Adv. Healthc. Mater</source> <volume>11</volume>, <fpage>e2200990</fpage>. <pub-id pub-id-type="doi">10.1002/adhm.202200990</pub-id>
</citation>
</ref>
<ref id="B133">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zheng</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Lei</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>H. B.</given-names>
</name>
<name>
<surname>Jiang</surname>
<given-names>M. C.</given-names>
</name>
<name>
<surname>Zhou</surname>
<given-names>Z. T.</given-names>
</name>
<name>
<surname>Zhao</surname>
<given-names>Y. Q.</given-names>
</name>
<etal/>
</person-group> (<year>2022b</year>). <article-title>A ROS-responsive liposomal composite hydrogel integrating improved mitochondrial function and pro-angiogenesis for efficient treatment of myocardial infarction</article-title>. <source>Adv. Healthc. Mater.</source> <volume>11</volume>, <fpage>e2200990</fpage>. <pub-id pub-id-type="doi">10.1002/adhm.202200990</pub-id>
</citation>
</ref>
<ref id="B134">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhou</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Yu</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Luo</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Lan</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>P.</given-names>
</name>
<etal/>
</person-group> (<year>2021</year>). <article-title>Myocardial ischemia-reperfusion injury: therapeutics from a mitochondria-centric perspective</article-title>. <source>Cardiology</source> <volume>146</volume>, <fpage>781</fpage>&#x2013;<lpage>792</lpage>. <pub-id pub-id-type="doi">10.1159/000518879</pub-id>
</citation>
</ref>
<ref id="B135">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ziegler</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Yap</surname>
<given-names>M. L.</given-names>
</name>
<name>
<surname>Hu</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Peter</surname>
<given-names>K.</given-names>
</name>
</person-group> (<year>2019</year>). <article-title>A self-assembled fluorescent nanoprobe for imaging and therapy of cardiac ischemia/reperfusion injury</article-title>. <source>Adv. Ther.</source> <volume>2</volume>, <fpage>1800133</fpage>. <pub-id pub-id-type="doi">10.1002/adtp.201800133</pub-id>
</citation>
</ref>
</ref-list>
</back>
</article>